<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>ema-combined-h-2755-en-annotated</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Überschrift 1 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:31.7pt;
	text-indent:-31.7pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h2
	{mso-style-link:"Überschrift 2 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:49.7pt;
	text-indent:-49.7pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h3
	{mso-style-link:"Überschrift 3 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h4
	{mso-style-link:"Überschrift 4 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:.95in;
	text-indent:-.95in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Überschrift 5 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.1in;
	text-indent:-1.1in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h6
	{mso-style-link:"Überschrift 6 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:89.9pt;
	text-indent:-1.25in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Überschrift 7 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.35in;
	text-indent:-1.35in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Überschrift 8 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.45in;
	text-indent:-1.45in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Überschrift 9 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:24.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:48.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:96.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:31.7pt;
	text-indent:-31.7pt;
	font-size:14.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:49.7pt;
	text-indent:-49.7pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:.8in;
	text-indent:-.8in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:.95in;
	text-indent:-.95in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:1.1in;
	text-indent:-1.1in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:1.35in;
	text-indent:-1.35in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:1.45in;
	text-indent:-1.45in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:1.55in;
	text-indent:-1.55in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Fußnotentext Zchn";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Kommentartext Zchn1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Kopfzeile Zchn";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Fußzeile Zchn";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Beschriftung\,12\,12+\,Caption 12pt\,Caption 12pt+\,Designation\,c\,cap\,ctdCaption";
	mso-style-link:"Beschriftung Zchn\,12 Zchn\,12+ Zchn\,Caption 12pt Zchn\,Caption 12pt+ Zchn\,Designation Zchn\,c Zchn\,cap Zchn\,ctdCaption Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:0in;
	margin-right:27.35pt;
	margin-bottom:0in;
	margin-left:1.5in;
	text-indent:-1.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnotentext Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Makrotext Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Titel Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Grußformel Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Unterschrift Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Textkörper Zchn";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Textkörper-Zeileneinzug Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Nachrichtenkopf Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Untertitel Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Anrede Zchn";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Datum Zchn";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Textkörper-Erstzeileneinzug Zchn";
	margin:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Textkörper-Erstzeileneinzug 2 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Fuß\/-Endnotenüberschrift Zchn";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Textkörper 2 Zchn";
	margin:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Textkörper 3 Zchn";
	margin:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Textkörper-Einzug 2 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Textkörper-Einzug 3 Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:none;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:none;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Dokumentstruktur Zchn";
	margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Nur Text Zchn";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-Mail-Signatur Zchn";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Adresse Zchn";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
code
	{font-family:"Courier New";}
kbd
	{font-family:"Courier New";}
pre
	{mso-style-link:"HTML Vorformatiert Zchn";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
samp
	{font-family:"Courier New";}
tt
	{font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Kommentarthema Zchn";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Sprechblasentext Zchn";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:115%;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
span.berschrift1Zchn
	{mso-style-name:"Überschrift 1 Zchn";
	mso-style-link:"Überschrift 1";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift2Zchn
	{mso-style-name:"Überschrift 2 Zchn";
	mso-style-link:"Überschrift 2";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift3Zchn
	{mso-style-name:"Überschrift 3 Zchn";
	mso-style-link:"Überschrift 3";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift4Zchn
	{mso-style-name:"Überschrift 4 Zchn";
	mso-style-link:"Überschrift 4";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift5Zchn
	{mso-style-name:"Überschrift 5 Zchn";
	mso-style-link:"Überschrift 5";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift6Zchn
	{mso-style-name:"Überschrift 6 Zchn";
	mso-style-link:"Überschrift 6";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift7Zchn
	{mso-style-name:"Überschrift 7 Zchn";
	mso-style-link:"Überschrift 7";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift8Zchn
	{mso-style-name:"Überschrift 8 Zchn";
	mso-style-link:"Überschrift 8";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.berschrift9Zchn
	{mso-style-name:"Überschrift 9 Zchn";
	mso-style-link:"Überschrift 9";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.KopfzeileZchn
	{mso-style-name:"Kopfzeile Zchn";
	mso-style-link:Kopfzeile;
	font-family:"Times New Roman",serif;}
span.FuzeileZchn
	{mso-style-name:"Fußzeile Zchn";
	mso-style-link:Fußzeile;
	font-family:"Times New Roman",serif;}
span.KommentartextZchn1
	{mso-style-name:"Kommentartext Zchn1";
	mso-style-link:Kommentartext;
	font-family:"Times New Roman",serif;}
span.KommentarthemaZchn
	{mso-style-name:"Kommentarthema Zchn";
	mso-style-link:Kommentarthema;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.SprechblasentextZchn
	{mso-style-name:"Sprechblasentext Zchn";
	mso-style-link:Sprechblasentext;
	font-family:"Tahoma",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.FunotentextZchn
	{mso-style-name:"Fußnotentext Zchn";
	mso-style-link:Fußnotentext;
	font-family:"Times New Roman",serif;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Superscript
	{mso-style-name:Superscript;
	vertical-align:super;}
p.HeadingCentered, li.HeadingCentered, div.HeadingCentered
	{mso-style-name:"Heading Centered";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.ListBulletSmall, li.ListBulletSmall, div.ListBulletSmall
	{mso-style-name:"List Bullet Small";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.ListBulletIndent, li.ListBulletIndent, div.ListBulletIndent
	{mso-style-name:"List Bullet Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.NormalSingle, li.NormalSingle, div.NormalSingle
	{mso-style-name:"Normal Single";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.OutlineNumbering, li.OutlineNumbering, div.OutlineNumbering
	{mso-style-name:"Outline Numbering";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.EndnotentextZchn
	{mso-style-name:"Endnotentext Zchn";
	mso-style-link:Endnotentext;
	font-family:"Times New Roman",serif;}
p.TableHeader, li.TableHeader, div.TableHeader
	{mso-style-name:"Table Header";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.TableNoteInfo, li.TableNoteInfo, div.TableNoteInfo
	{mso-style-name:"Table Note Info";
	margin-top:0in;
	margin-right:12.25pt;
	margin-bottom:0in;
	margin-left:.15in;
	text-indent:-.15in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Subscript
	{mso-style-name:Subscript;
	vertical-align:sub;}
span.TableNote
	{mso-style-name:"Table Note";}
span.InstructionText
	{mso-style-name:"Instruction Text";
	color:red;
	display:none;
	font-style:italic;}
span.TextkrperZchn
	{mso-style-name:"Textkörper Zchn";
	mso-style-link:Textkörper;
	font-family:"Times New Roman",serif;}
span.Textkrper2Zchn
	{mso-style-name:"Textkörper 2 Zchn";
	mso-style-link:"Textkörper 2";
	font-family:"Times New Roman",serif;}
span.Textkrper3Zchn
	{mso-style-name:"Textkörper 3 Zchn";
	mso-style-link:"Textkörper 3";
	font-family:"Times New Roman",serif;}
span.Textkrper-ErstzeileneinzugZchn
	{mso-style-name:"Textkörper-Erstzeileneinzug Zchn";
	mso-style-link:Textkörper-Erstzeileneinzug;
	font-family:"Times New Roman",serif;}
span.Textkrper-ZeileneinzugZchn
	{mso-style-name:"Textkörper-Zeileneinzug Zchn";
	mso-style-link:Textkörper-Zeileneinzug;
	font-family:"Times New Roman",serif;}
span.Textkrper-Erstzeileneinzug2Zchn
	{mso-style-name:"Textkörper-Erstzeileneinzug 2 Zchn";
	mso-style-link:"Textkörper-Erstzeileneinzug 2";
	font-family:"Times New Roman",serif;}
span.Textkrper-Einzug2Zchn
	{mso-style-name:"Textkörper-Einzug 2 Zchn";
	mso-style-link:"Textkörper-Einzug 2";
	font-family:"Times New Roman",serif;}
span.Textkrper-Einzug3Zchn
	{mso-style-name:"Textkörper-Einzug 3 Zchn";
	mso-style-link:"Textkörper-Einzug 3";
	font-family:"Times New Roman",serif;}
span.GruformelZchn
	{mso-style-name:"Grußformel Zchn";
	mso-style-link:Grußformel;
	font-family:"Times New Roman",serif;}
span.DatumZchn
	{mso-style-name:"Datum Zchn";
	mso-style-link:Datum;
	font-family:"Times New Roman",serif;}
span.DokumentstrukturZchn
	{mso-style-name:"Dokumentstruktur Zchn";
	mso-style-link:Dokumentstruktur;
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.E-Mail-SignaturZchn
	{mso-style-name:"E-Mail-Signatur Zchn";
	mso-style-link:E-Mail-Signatur;
	font-family:"Times New Roman",serif;}
span.HTMLAdresseZchn
	{mso-style-name:"HTML Adresse Zchn";
	mso-style-link:"HTML Adresse";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLVorformatiertZchn
	{mso-style-name:"HTML Vorformatiert Zchn";
	mso-style-link:"HTML Vorformatiert";
	font-family:"Courier New";}
span.MakrotextZchn
	{mso-style-name:"Makrotext Zchn";
	mso-style-link:Makrotext;
	font-family:"Courier New";}
span.NachrichtenkopfZchn
	{mso-style-name:"Nachrichtenkopf Zchn";
	mso-style-link:Nachrichtenkopf;
	font-family:"Arial",sans-serif;
	background:#CCCCCC;}
span.Fu-EndnotenberschriftZchn
	{mso-style-name:"Fuß\/-Endnotenüberschrift Zchn";
	mso-style-link:"Fuß\/-Endnotenüberschrift";
	font-family:"Times New Roman",serif;}
span.NurTextZchn
	{mso-style-name:"Nur Text Zchn";
	mso-style-link:"Nur Text";
	font-family:"Courier New";}
span.AnredeZchn
	{mso-style-name:"Anrede Zchn";
	mso-style-link:Anrede;
	font-family:"Times New Roman",serif;}
span.UnterschriftZchn
	{mso-style-name:"Unterschrift Zchn";
	mso-style-link:Unterschrift;
	font-family:"Times New Roman",serif;}
span.UntertitelZchn
	{mso-style-name:"Untertitel Zchn";
	mso-style-link:Untertitel;
	font-family:"Arial",sans-serif;}
span.TitelZchn
	{mso-style-name:"Titel Zchn";
	mso-style-link:Titel;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.BMSHeading1, li.BMSHeading1, div.BMSHeading1
	{mso-style-name:"BMS Heading 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
p.BMSHeading2, li.BMSHeading2, div.BMSHeading2
	{mso-style-name:"BMS Heading 2";
	mso-style-link:"BMS Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.4in;
	text-indent:-.4in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.BMSHeading3, li.BMSHeading3, div.BMSHeading3
	{mso-style-name:"BMS Heading 3";
	mso-style-link:"BMS Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.5in;
	text-indent:-.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.BMSHeading4, li.BMSHeading4, div.BMSHeading4
	{mso-style-name:"BMS Heading 4";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.6in;
	text-indent:-.6in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;
	font-style:italic;}
p.BMSBodyText, li.BMSBodyText, div.BMSBodyText
	{mso-style-name:"BMS Body Text";
	mso-style-link:"BMS Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.BMSBodyTextChar
	{mso-style-name:"BMS Body Text Char";
	mso-style-link:"BMS Body Text";
	font-family:"Times New Roman",serif;
	color:black;}
span.BMSHeading2Char
	{mso-style-name:"BMS Heading 2 Char";
	mso-style-link:"BMS Heading 2";
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
span.BMSHeading3Char
	{mso-style-name:"BMS Heading 3 Char";
	mso-style-link:"BMS Heading 3";
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.BasicParagraph, li.BasicParagraph, div.BasicParagraph
	{mso-style-name:"\[Basic Paragraph\]";
	margin:0in;
	line-height:120%;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.BMSTableHeader, li.BMSTableHeader, div.BMSTableHeader
	{mso-style-name:"BMS Table Header";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMSTableText, li.BMSTableText, div.BMSTableText
	{mso-style-name:"BMS Table Text";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.BMSTableHeaderLarge, li.BMSTableHeaderLarge, div.BMSTableHeaderLarge
	{mso-style-name:"BMS Table Header Large";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:10.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	mso-style-link:"Table text rows \(Agency\) Char";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.BMSSuperscript
	{mso-style-name:"BMS Superscript";
	vertical-align:super;}
span.hps
	{mso-style-name:hps;}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";
	font-family:"Arial",sans-serif;}
span.value
	{mso-style-name:value;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading4Agency, li.No-numheading4Agency, div.No-numheading4Agency
	{mso-style-name:"No-num heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	mso-style-link:"No-num heading 5 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading5AgencyChar
	{mso-style-name:"No-num heading 5 \(Agency\) Char";
	mso-style-link:"No-num heading 5 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.BeschriftungZchn
	{mso-style-name:"Beschriftung Zchn\,12 Zchn\,12+ Zchn\,Caption 12pt Zchn\,Caption 12pt+ Zchn\,Designation Zchn\,c Zchn\,cap Zchn\,ctdCaption Zchn";
	mso-style-link:"Beschriftung\,12\,12+\,Caption 12pt\,Caption 12pt+\,Designation\,c\,cap\,ctdCaption";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.a, li.a, div.a
	{mso-style-name:"\03A0\03B1\03C1\03AC\03B3\03C1\03B1\03C6\03BF\03C2 \03BB\03AF\03C3\03C4\03B1\03C2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.aCxSpFirst, li.aCxSpFirst, div.aCxSpFirst
	{mso-style-name:"\03A0\03B1\03C1\03AC\03B3\03C1\03B1\03C6\03BF\03C2 \03BB\03AF\03C3\03C4\03B1\03C2CxSpFirst";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.aCxSpMiddle, li.aCxSpMiddle, div.aCxSpMiddle
	{mso-style-name:"\03A0\03B1\03C1\03AC\03B3\03C1\03B1\03C6\03BF\03C2 \03BB\03AF\03C3\03C4\03B1\03C2CxSpMiddle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.aCxSpLast, li.aCxSpLast, div.aCxSpLast
	{mso-style-name:"\03A0\03B1\03C1\03AC\03B3\03C1\03B1\03C6\03BF\03C2 \03BB\03AF\03C3\03C4\03B1\03C2CxSpLast";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.HeadingcentredAgency, li.HeadingcentredAgency, div.HeadingcentredAgency
	{mso-style-name:"Heading centred \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin:0in;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.FooterblueAgency, li.FooterblueAgency, div.FooterblueAgency
	{mso-style-name:"Footer blue \(Agency\)";
	mso-style-link:"Footer blue \(Agency\) Char Char";
	margin:0in;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.PagenumberAgency, li.PagenumberAgency, div.PagenumberAgency
	{mso-style-name:"Page number \(Agency\)";
	mso-style-link:"Page number \(Agency\) Char Char";
	margin:0in;
	text-align:right;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.PagenumberAgencyCharChar
	{mso-style-name:"Page number \(Agency\) Char Char";
	mso-style-link:"Page number \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterblueAgencyCharChar
	{mso-style-name:"Footer blue \(Agency\) Char Char";
	mso-style-link:"Footer blue \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
p.DisclaimerAgency, li.DisclaimerAgency, div.DisclaimerAgency
	{mso-style-name:"Disclaimer \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:0in;
	line-height:7.5pt;
	font-size:6.5pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.DocsubtitleAgency, li.DocsubtitleAgency, div.DocsubtitleAgency
	{mso-style-name:"Doc subtitle \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:32.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.DoctitleAgency, li.DoctitleAgency, div.DoctitleAgency
	{mso-style-name:"Doc title \(Agency\)";
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:18.0pt;
	font-size:16.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;}
span.EndnotereferenceAgency
	{mso-style-name:"Endnote reference \(Agency\)";
	font-family:"Verdana",sans-serif;
	vertical-align:super;}
p.EndnotetextAgency, li.EndnotetextAgency, div.EndnotetextAgency
	{mso-style-name:"Endnote text \(Agency\)";
	margin:0in;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.FigureAgency, li.FigureAgency, div.FigureAgency
	{mso-style-name:"Figure \(Agency\)";
	margin:0in;
	text-align:center;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.FigureheadingAgency, li.FigureheadingAgency, div.FigureheadingAgency
	{mso-style-name:"Figure heading \(Agency\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.3in;
	text-indent:-.3in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.FootnotereferenceAgency
	{mso-style-name:"Footnote reference \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:windowtext;
	vertical-align:super;}
p.FootnotetextAgency, li.FootnotetextAgency, div.FootnotetextAgency
	{mso-style-name:"Footnote text \(Agency\)";
	margin:0in;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.HeaderAgency, li.HeaderAgency, div.HeaderAgency
	{mso-style-name:"Header \(Agency\)";
	margin:0in;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.Heading1Agency, li.Heading1Agency, div.Heading1Agency
	{mso-style-name:"Heading 1 \(Agency\)";
	mso-style-link:"Heading 1 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading2Agency, li.Heading2Agency, div.Heading2Agency
	{mso-style-name:"Heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:27.0pt;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading3Agency, li.Heading3Agency, div.Heading3Agency
	{mso-style-name:"Heading 3 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading4Agency, li.Heading4Agency, div.Heading4Agency
	{mso-style-name:"Heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading5Agency, li.Heading5Agency, div.Heading5Agency
	{mso-style-name:"Heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading6Agency, li.Heading6Agency, div.Heading6Agency
	{mso-style-name:"Heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading7Agency, li.Heading7Agency, div.Heading7Agency
	{mso-style-name:"Heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading8Agency, li.Heading8Agency, div.Heading8Agency
	{mso-style-name:"Heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading9Agency, li.Heading9Agency, div.Heading9Agency
	{mso-style-name:"Heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading1Agency, li.No-numheading1Agency, div.No-numheading1Agency
	{mso-style-name:"No-num heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading6Agency, li.No-numheading6Agency, div.No-numheading6Agency
	{mso-style-name:"No-num heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading7Agency, li.No-numheading7Agency, div.No-numheading7Agency
	{mso-style-name:"No-num heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading8Agency, li.No-numheading8Agency, div.No-numheading8Agency
	{mso-style-name:"No-num heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading9Agency, li.No-numheading9Agency, div.No-numheading9Agency
	{mso-style-name:"No-num heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-TOCheadingAgency, li.No-TOCheadingAgency, div.No-TOCheadingAgency
	{mso-style-name:"No-TOC heading \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.RefAgency, li.RefAgency, div.RefAgency
	{mso-style-name:"Ref\. \(Agency\)";
	margin:0in;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;}
p.TablefirstrowAgency, li.TablefirstrowAgency, div.TablefirstrowAgency
	{mso-style-name:"Table first row \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TableheadingAgency, li.TableheadingAgency, div.TableheadingAgency
	{mso-style-name:"Table heading \(Agency\)";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableFigurenoteAgency, li.TableFigurenoteAgency, div.TableFigurenoteAgency
	{mso-style-name:"Table\/Figure note \(Agency\)";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Verdana",sans-serif;}
p.SpecialcommentAgency, li.SpecialcommentAgency, div.SpecialcommentAgency
	{mso-style-name:"Special comment \(Agency\)";
	margin:0in;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;
	color:red;}
p.AFPstyle, li.AFPstyle, div.AFPstyle
	{mso-style-name:AFPstyle;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	line-height:150%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.DoccategoryheadingAgency, li.DoccategoryheadingAgency, div.DoccategoryheadingAgency
	{mso-style-name:"Doc category heading \(Agency\)";
	margin-top:28.35pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:#003399;
	font-weight:bold;}
p.PargrafodaLista1, li.PargrafodaLista1, div.PargrafodaLista1
	{mso-style-name:"Parágrafo da Lista1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.PargrafodaLista1CxSpFirst, li.PargrafodaLista1CxSpFirst, div.PargrafodaLista1CxSpFirst
	{mso-style-name:"Parágrafo da Lista1CxSpFirst";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.PargrafodaLista1CxSpMiddle, li.PargrafodaLista1CxSpMiddle, div.PargrafodaLista1CxSpMiddle
	{mso-style-name:"Parágrafo da Lista1CxSpMiddle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.PargrafodaLista1CxSpLast, li.PargrafodaLista1CxSpLast, div.PargrafodaLista1CxSpLast
	{mso-style-name:"Parágrafo da Lista1CxSpLast";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.Textkrpernummeriert, li.Textkrpernummeriert, div.Textkrpernummeriert
	{mso-style-name:"Textkörper nummeriert";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:17.85pt;
	text-align:justify;
	text-indent:-17.85pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.Heading1AgencyChar
	{mso-style-name:"Heading 1 \(Agency\) Char";
	mso-style-link:"Heading 1 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.CarcterCarcter1
	{mso-style-name:"Carácter Carácter1";
	font-family:"Verdana",sans-serif;}
p.Reviso1, li.Reviso1, div.Reviso1
	{mso-style-name:Revisão1;
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.TabletextrowsAgencyChar
	{mso-style-name:"Table text rows \(Agency\) Char";
	mso-style-link:"Table text rows \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Header3, li.Header3, div.Header3
	{mso-style-name:"Header 3";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:69.5pt;
	text-indent:-21.25pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
span.FooterChar1
	{mso-style-name:"Footer Char1";
	font-family:"MS Mincho",serif;}
span.HeaderChar1
	{mso-style-name:"Header Char1";
	font-family:"MS Mincho",serif;}
span.CommentTextChar2
	{mso-style-name:"Comment Text Char2";
	font-family:"MS Mincho",serif;}
span.BalloonTextChar1
	{mso-style-name:"Balloon Text Char1";
	font-family:"Tahoma",sans-serif;}
span.CharChar14
	{mso-style-name:"Char Char14";
	font-family:"MS Mincho",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";
	font-family:"Times New Roman",serif;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:6.0pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin-top:0in;
	margin-right:4.25pt;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
p.SynopsisText, li.SynopsisText, div.SynopsisText
	{mso-style-name:SynopsisText;
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.a0, li.a0, div.a0
	{mso-style-name:"";
	mso-style-link:"Kommentartext Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.KommentartextZchn
	{mso-style-name:"Kommentartext Zchn";
	mso-style-link:"";
	font-family:"Times New Roman",serif;}
p.PargrafodaLista, li.PargrafodaLista, div.PargrafodaLista
	{mso-style-name:"Parágrafo da Lista";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.PargrafodaListaCxSpFirst, li.PargrafodaListaCxSpFirst, div.PargrafodaListaCxSpFirst
	{mso-style-name:"Parágrafo da ListaCxSpFirst";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.PargrafodaListaCxSpMiddle, li.PargrafodaListaCxSpMiddle, div.PargrafodaListaCxSpMiddle
	{mso-style-name:"Parágrafo da ListaCxSpMiddle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.PargrafodaListaCxSpLast, li.PargrafodaListaCxSpLast, div.PargrafodaListaCxSpLast
	{mso-style-name:"Parágrafo da ListaCxSpLast";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.Reviso, li.Reviso, div.Reviso
	{mso-style-name:Revisão;
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:#65B4B4;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:#FF4B4B;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><strong><span
lang=EN-GB>&nbsp;</span></strong></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>ANNEX&nbsp;I</span></b></p>

<p class=MsoNormal align=center style='margin-right:4.25pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>1.       NAME OF THE MEDICINAL
PRODUCT</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>2.       QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
vial contains 300&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
vial contains 400&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
pre&#8209;filled&nbsp;syringe contains 300&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
pre&#8209;filled&nbsp;syringe contains 400&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>After
reconstitution each ml of suspension contains 200&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>For
the full list of excipients, see section&nbsp;6.1.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>3.       PHARMACEUTICAL FORM</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Powder
and solvent for prolonged-release suspension for injection</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Powder:
white to off-white</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Solvent:
clear solution</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.       CLINICAL PARTICULARS</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.1     Therapeutic
indications</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena is indicated for maintenance treatment of schizophrenia in adult
patients stabilised with oral aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.2     Posology and method of
administration</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Posology</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>For
patients who have never taken aripiprazole, tolerability with oral aripiprazole
must occur prior to initiating treatment with Abilify Maintena.</span></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Titration
of the dose </span></em><em><span lang=EN-GB style='color:black;font-style:
normal'>for Abilify Maintena is not required. </span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>starting
dose can be administered by following one of two regimens: </span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        One injection start: On
the day of initiation, administer one injection of 400&nbsp;mg Abilify Maintena
and continue treatment with 10&nbsp;mg to 20&nbsp;mg oral aripiprazole per day for
14&nbsp;consecutive days to maintain therapeutic aripiprazole concentrations
during initiation of therapy. </span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        Two injection start:
On the day of initiation, administer two separate injections of 400&nbsp;mg
Abilify Maintena at separate injection sites (see method of administration), along
with one 20&nbsp;mg dose of oral aripiprazole. </span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>After
the </span></em><em><span lang=EN-GB style='color:black;font-style:normal'>injection
start, the </span></em><em><span lang=EN-GB style='color:black;font-style:normal'>recommended
maintenance dose of Abilify Maintena is 400&nbsp;mg.</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'> Abilify Maintena</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'> should be administered once
monthly as a single injection (no sooner than 26&nbsp;days after the previous
injection).</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>
</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>If there
are adverse reactions with the 400&nbsp;mg dosage, reduction of the dose to
300&nbsp;mg once monthly should be considered.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Missed
doses</span></u></em></p>

<p class=MsoNormal style='margin-left:.5in'><em><span lang=EN-GB
style='color:black;background:yellow;font-style:normal'>&nbsp;</span></em></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=614 colspan=2 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>Missed doses</span></b></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Timing of Missed Dose</span></b></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>Action</span></b></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>If 2<sup>nd</sup> or 3<sup>rd</sup>&nbsp;dose is missed and time
  since last injection is:</span></b></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&gt;&nbsp;4&nbsp;weeks
  and&nbsp;&lt;&nbsp;5&nbsp;weeks </span></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
  injection should be administered as soon as possible and then the monthly
  injection schedule should be resumed.</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&gt;&nbsp;5&nbsp;weeks
  </span></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Concomitant
  oral aripiprazole should be restarted for 14&nbsp;days with next administered
  injection</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>
  or two separate injections given at one time, along with a single dose of 20&nbsp;mg
  oral aripiprazole. Monthly injection schedule should then resume</span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'>.</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>If 4<sup>th</sup> or subsequent doses are missed (i.e., after
  attainment of steady state) and time since last injection is:</span></b></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&gt;&nbsp;4&nbsp;weeks
  and&nbsp;&lt;&nbsp;6&nbsp;weeks</span></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
  injection should be administered as soon as possible and then the monthly
  injection schedule should be resumed.</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=246 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&gt;&nbsp;6&nbsp;weeks</span></em></p>
  </td>
  <td width=369 valign=top style='width:276.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Concomitant
  oral aripiprazole should be restarted for 14&nbsp;days with next administered
  injection </span></em><em><span lang=EN-GB style='color:black;font-style:
  normal'>or two separate injections given at one time, along with a single
  dose of 20&nbsp;mg oral aripiprazole. Monthly</span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'> injection schedule</span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'> should then resume</span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'>.</span></em></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Special
populations</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Elderly</span></em></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of <em><span
style='color:black;font-style:normal'>Abilify Maintena</span></em> in the
treatment of schizophrenia in patients 65&nbsp;years of age or older has not
been established (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Renal impairment</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>No
dosage adjustment is required for patients with renal impairment (see section&nbsp;5.2).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Hepatic impairment</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>No
dosage adjustment is required for patients with mild or moderate hepatic
impairment. In patients with severe hepatic impairment, the data available are
insufficient to establish recommendations. In these patients dosing should be
managed cautiously. Oral formulation should be preferred (see
section&nbsp;5.2).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><a name="_Hlk23773509"><em><span lang=EN-GB
style='color:black'>Known CYP2D6 poor metabolisers</span></em></a></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
patients who are known to be CYP2D6 poor metabolisers</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>: </span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        One injection start: The
starting dose should be 300&nbsp;mg Abilify Maintena and continue treatment with
prescribed dose of oral aripiprazole per day for 14&nbsp;consecutive days. </span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        Two injection start:
The starting dose should be 2 separate injections of 300&nbsp;mg Abilify
Maintena (see method of administration) along with one single dose of the previous
prescribed dose of oral aripiprazole. </span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
patients who are known to be CYP2D6 poor metabolisers and concomitantly use a
strong CYP3A4 inhibitor:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        The one injection
start: The starting dose should be reduced to 200&nbsp;mg (see section&nbsp;4.5)
and continue treatment with the prescribed dose of oral aripiprazole per day
for 14&nbsp;consecutive days.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        Two injection start
is not to be used in patients who are known to be CYP2D6 poor metabolisers and
concomitantly use a strong CYP3A4 inhibitor.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>After
the injection start, see table below for the recommended maintenance dose of
Abilify Maintena. Abilify Maintena should be administered once monthly as a
single injection (no sooner than 26&nbsp;days after the previous injection).</span></em></p>

<p class=MsoNormal style='margin-left:.25in'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Maintenance dose</span></em><em><span
lang=EN-GB style='color:black'> adjustments due to interactions </span></em><i><span
lang=EN-GB style='color:black'>with CYP2D6 and/or CYP3A4 inhibitors and/or
CYP3A4 inducers</span></i></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Maintenance
dosage</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>
adjustments should be made in patients taking concomitant strong CYP3A4
inhibitors or strong CYP2D6 inhibitors for more than 14&nbsp;days. If the
CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be
increased to the previous dose (see section&nbsp;4.5). In case of adverse
reactions despite dose adjustments of Abilify Maintena, the necessity of
concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Concomitant
use of CYP3A4 inducers with Abilify Maintena should be avoided for more than
14&nbsp;days because the blood levels of aripiprazole are decreased and may be
below the effective levels (see section&nbsp;4.5).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
style='color:black;font-style:normal'>Maintenance dose</span></b></em><em><b><span
lang=EN-GB style='color:black;font-style:normal'> adjustments of Abilify Maintena
in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4
inhibitors, and/or CYP3A4 inducers for more than 14&nbsp;days</span></b></em></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:22.45pt'>
  <td width=378 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.45pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.45pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>Adjusted dose</span></b></em></p>
  </td>
 </tr>
 <tr style='height:11.2pt'>
  <td width=614 colspan=2 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Patients taking 400&nbsp;mg of Abilify Maintena</span></b></em></p>
  </td>
 </tr>
 <tr style='height:11.2pt'>
  <td width=378 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Strong
  CYP2D6 or strong CYP3A4 inhibitors</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.2pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>300&nbsp;mg</span></em></p>
  </td>
 </tr>
 <tr style='height:13.0pt'>
  <td width=378 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.0pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Strong
  CYP2D6 and strong CYP3A4 inhibitors</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>200&nbsp;mg*</span></em></p>
  </td>
 </tr>
 <tr style='height:11.65pt'>
  <td width=378 style='width:283.5pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>CYP3A4
  inducers</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Avoid use</span></em></p>
  </td>
 </tr>
 <tr style='height:8.95pt'>
  <td width=614 colspan=2 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Patients taking 300&nbsp;mg of Abilify Maintena</span></b></em></p>
  </td>
 </tr>
 <tr style='height:8.5pt'>
  <td width=378 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Strong
  CYP2D6 or strong CYP3A4 inhibitors</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>200&nbsp;mg*</span></em></p>
  </td>
 </tr>
 <tr style='height:8.95pt'>
  <td width=378 valign=top style='width:283.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Strong
  CYP2D6 and strong CYP3A4 inhibitors</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:8.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>160&nbsp;mg*</span></em></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=378 style='width:283.5pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>CYP3A4
  inducers</span></em></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Avoid use</span></em></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><em><span
lang=EN-GB style='font-size:8.0pt;font-style:normal'>*    </span></em><span
lang=EN-GB style='font-size:8.0pt'>200&nbsp;mg and 160&nbsp;mg can be achieved via
adjustment of the injection volume only by using Abilify Maintena powder and
solvent for </span><span lang=EN-GB style='font-size:8.0pt'>       </span><span
lang=EN-GB style='font-size:8.0pt'>prolonged-release suspension for injection.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Paediatric
population</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
safety and efficacy of Abilify Maintena in children and adolescents aged 0&#8209;17&nbsp;years
have not been established. No data are available.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Method
of administration</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena is only intended for intramuscular use and should not be administered
intravenously or subcutaneously. It should only be administered by a healthcare
professional.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
suspension should be injected slowly as a single injection (doses must not be
divided) into the gluteal or deltoid muscle. Care should be taken to avoid
inadvertent injection into a blood vessel.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If initiating with the
two injection start, inject into two different sites in two different muscles.
DO NOT inject both injections concomitantly into the same deltoid or gluteal
muscle.</span><span lang=EN-GB style='color:#0070C0'> </span><span lang=EN-GB>For
known CYP2D6 poor metabolisers administer in either two separate deltoid
muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal
muscles.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Full instructions for
use and handling of Abilify Maintena are provided in the package leaflet
(information intended for healthcare professionals).</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For instructions on
reconstitution of the medicinal product before administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.3     Contraindications</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><em><b><span lang=EN-GB style='color:black;font-style:normal'>4.4     Special
warnings and precautions for use</span></b></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='font-style:normal'>During antipsychotic treatment, improvement in the
patient's clinical condition may take several days to some weeks. Patients
should be closely monitored throughout this period.</span></em></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Use in patients who are in an acutely
agitated or severely psychotic state</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Abilify Maintena should not be used to
manage acutely agitated or severely psychotic states when immediate symptom
control is warranted.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Suicidality</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
occurrence of suicidal behaviour is inherent in psychotic illnesses, and in
some cases has been reported early after initiation or switch of antipsychotic
treatment, including treatment with aripiprazole (see section&nbsp;4.8). Close
supervision of high risk patients should accompany antipsychotic treatment.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Cardiovascular disorders</span></u></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole
should be used with caution in patients with known cardiovascular disease
(history of myocardial infarction or ischaemic heart disease, heart failure, or
conduction abnormalities), cerebrovascular disease, conditions which would
predispose patients to hypotension (dehydration, hypovolemia, and treatment with
antihypertensive medicinal products) or hypertension, including accelerated or
malignant. Cases of venous thromboembolism (VTE) have been reported with
antipsychotic medicinal products. Since patients treated with antipsychotics
often present with acquired risk factors for VTE, all possible risk factors for
VTE should be identified before and during treatment with aripiprazole and
preventive measures undertaken (see section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>QT
prolongation</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
clinical trials of treatment with oral aripiprazole, the incidence of QT
prolongation was comparable to placebo. Aripiprazole should be used with
caution in patients with a family history of QT prolongation (see
section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Tardive
dyskinesia</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
clinical trials of one year or less duration, there were uncommon reports of
treatment emergent dyskinesia during treatment with aripiprazole. If signs and
symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose
reduction or discontinuation should be considered (see section&nbsp;4.8). These
symptoms can temporally deteriorate or can even arise after discontinuation of
treatment.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Neuroleptic
Malignant Syndrome (NMS)</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>NMS
is a potentially fatal symptom complex associated with antipsychotics. In
clinical trials, rare cases of NMS were reported during treatment with
aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity,
altered mental status and evidence of autonomic instability (irregular pulse or
blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs
may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis),
and acute renal failure. However, elevated creatine phosphokinase and
rhabdomyolysis, not necessarily in association with NMS, have also been
reported. If a patient develops signs and symptoms indicative of NMS, or
presents with unexplained high fever without additional clinical manifestations
of NMS, all antipsychotics, including aripiprazole, must be discontinued (see
section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Seizure</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
clinical trials, uncommon cases of seizure were reported during treatment with
aripiprazole. Therefore, aripiprazole should be used with caution in patients
who have a history of seizure disorder or have conditions associated with
seizures (see section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly patients with dementia-related
psychosis</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Increased mortality</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In three
placebo-controlled trials of oral aripiprazole in elderly patients with
psychosis associated with Alzheimer's disease (n&nbsp;=&nbsp;938; mean age:
82.4&nbsp;years; range: 56&#8209;99&nbsp;years), patients treated with
aripiprazole were at an increased risk of death compared to placebo. The rate
of death in oral aripiprazole-treated patients was 3.5&nbsp;% compared to
1.7&nbsp;% in placebo. Although the causes of deaths were varied, most of the
deaths appeared to be either cardiovascular (e.g. heart failure, sudden death)
or infectious (e.g. pneumonia) in nature (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Cerebrovascular adverse reactions</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the same
trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke,
transient ischaemic attack), including fatalities, were reported in patients
(mean age: 84&nbsp;years; range: 78&#8209;88&nbsp;years). Overall, 1.3&nbsp;%
of oral aripiprazole-treated patients reported cerebrovascular adverse
reactions compared with 0.6&nbsp;% of placebo-treated patients in these trials.
This difference was not statistically significant. However, in one of these
trials, a fixed-dose trial, there was a significant dose- response relationship
for cerebrovascular adverse reactions in patients treated with aripiprazole
(see section&nbsp;4.8).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole</span></em><span
lang=EN-GB style='color:black'> is not indicated for the treatment of patients
with dementia-related psychosis.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Hyperglycaemia
and diabetes mellitus</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Hyperglycaemia,
in some cases extreme and associated with ketoacidosis or hyperosmolar coma or
death, has been reported in patients treated with aripiprazole. Risk factors
that may predispose patients to severe complications include obesity and family
history of diabetes. Patients treated with aripiprazole should be observed for
signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia
and weakness) and patients with diabetes mellitus or with risk factors for
diabetes mellitus should be monitored regularly for worsening of glucose
control (see section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Hypersensitivity</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Hypersensitivity
reactions, characterised by allergic symptoms, may occur with aripiprazole (see
section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Weight gain</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;background:yellow;
font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Weight gain is commonly
seen in schizophrenic patients due to use of antipsychotics known to cause
weight gain, co-morbidities, poorly managed life-style and might lead to severe
complications. <em><span style='font-style:normal'>Weight gain has been
reported post-marketing among patients prescribed oral aripiprazole. When seen,
it is usually in those with significant risk factors such as history of
diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole
has not been shown to induce clinically relevant weight gain (see section&nbsp;4.8).</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Dysphagia</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Oesophageal
dysmotility and aspiration have been associated with the use of aripiprazole.
Aripiprazole should be used cautiously in patients at risk for aspiration
pneumonia.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>Patients can experience increased urges,
particularly for gambling, and the inability to control these urges while
taking aripiprazole. Other urges, reported, include: increased sexual urges,
compulsive shopping, binge or compulsive eating, and other impulsive and
compulsive behaviours. It is important for prescribers to ask patients or their
caregivers specifically about the development of new or increased gambling
urges, sexual urges, compulsive shopping, binge or compulsive eating, or other
urges while being treated with aripiprazole. It should be noted that
impulse-control symptoms can be associated with the underlying disorder;
however, in some cases, urges were reported to have stopped when the dose was
reduced or the medicinal productation was discontinued. Impulse control
disorders may result in harm to the patient and others if not recognised. </span></em><span
lang=EN-GB>A dose reduction or stopping of the medicinal product should be
considered if a patient develops such urges <em><span style='color:black;
font-style:normal'>(see section&nbsp;4.8</span></em>).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Falls</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Aripiprazole
may cause somnolence, postural hypotension, motor and sensory instability,
which may lead to falls. Caution should be taken when treating patients at
higher risk, and a lower starting dose should be considered (e.g., elderly or
debilitated patients; see section 4.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Abilify Maintena contains less than 1&nbsp;mmol
of sodium (23&nbsp;mg) per dose.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><em><b><span lang=EN-GB style='color:black;font-style:normal'>4.5     Interaction
with other medicinal products and other forms of interaction</span></b></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>No
interaction studies have been performed with Abilify Maintena. The information
below is obtained from studies with oral aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Due
to its &#945;1-adrenergic receptor antagonism, aripiprazole has the potential
to enhance the effect of certain antihypertensive medicinal products.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Given
the primary CNS effects of aripiprazole, caution should be used when
aripiprazole is administered in combination with alcohol or other CNS medicinal
products with overlapping adverse reactions such as sedation (see
section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
aripiprazole is administered concomitantly with medicinal products known to
cause QT prolongation or electrolyte imbalance, caution should be used.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Potential
for other medicinal products to affect aripiprazole</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Quinidine and other
strong CYP2D6 inhibitors</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor
of CYP2D6 (quinidine) increased aripiprazole AUC by 107&nbsp;%, while C<sub>max</sub>
was unchanged. The AUC and C<sub>max</sub> of dehydro-aripiprazole, the active
metabolite, decreased by 32&nbsp;% and 47&nbsp;%, respectively. Other strong
inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to
have similar effects and similar dose reduction should, therefore, be applied
(see section&nbsp;4.2).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Ketoconazole and
other strong CYP3A4 inhibitors</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor
of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max</sub> by
63&nbsp;% and 37&nbsp;%, respectively. The AUC and C<sub>max</sub> of
dehydro-aripiprazole increased by 77&nbsp;% and 43&nbsp;%, respectively. In
CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may
result in higher plasma concentrations of aripiprazole compared to that in
CYP2D6 extensive metabolisers (see section&nbsp;4.2). When considering
concomitant administration of ketoconazole or other potent CYP3A4 inhibitors
with aripiprazole, potential benefits should outweigh the potential risks to
the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV
protease inhibitors may be expected to have similar effects and similar dose
reductions should, therefore, be applied (see section&nbsp;4.2). Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should
be increased to the dose prior to the initiation of the concomitant therapy.
When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram)
are used concomitantly with aripiprazole, modest increases in plasma
aripiprazole concentrations may be expected.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Carbamazepine and
other CYP3A4 inducers</span></em></p>

<p class=MsoNormal><span class=BMSHeading3Char><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'>Following
concomitant administration of carbamazepine, a strong inducer of CYP3A4, and
oral aripiprazole</span></span><span class=BMSHeading3Char><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'> </span></i></span><em><span
lang=EN-GB style='color:black;font-style:normal'>to patients with schizophrenia
or schizoaffective disorder, the geometric means of C<sub>max</sub> and AUC for
aripiprazole were 68&nbsp;% and 73&nbsp;% lower, respectively, compared to when
oral aripiprazole (30&nbsp;mg) was administered alone. Similarly, for
dehydro-aripiprazole the geometric means of C<sub>max</sub> and AUC after
carbamazepine co-administration were 69&nbsp;% and 71&nbsp;% lower,
respectively, than those following treatment with oral aripiprazole alone. Concomitant
administration of Abilify Maintena and other inducers of CYP3A4 (such as
rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,
nevirapine and St. John's Wort) may be expected to have similar effects. The
concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided
because the blood levels of aripiprazole are decreased and may be below the
effective levels.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><i><span lang=EN-GB>Serotonin syndrome</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cases of serotonin syndrome have been
reported in patients taking aripiprazole, and possible signs and symptoms for
this condition can occur especially in cases of concomitant use with other
serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products
that are known to increase aripiprazole concentrations (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><em><b><span lang=EN-GB style='color:black;font-style:normal'>4.6     Fertility,
pregnancy and lactation</span></b></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Pregnancy</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>There are no adequate and well-controlled trials of
aripiprazole in pregnant women. Congenital anomalies have been reported;
however, causal relationship with aripiprazole could not be established. Animal
studies could not exclude potential developmental toxicity (see
section&nbsp;5.3). Patients must be advised to notify their physician if they
become pregnant or intend to become pregnant during treatment with <em><span
style='font-style:normal'>aripiprazole</span></em>. Due to insufficient safety
information in humans and concerns raised by animal reproductive studies, this
medicinal product should not be used in pregnancy unless the expected benefit
clearly justifies the potential risk to the foetus.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Prescribers
need to be aware of the long-acting properties of <em><span style='color:black;
font-style:normal'>Abilify Maintena</span></em>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>New-born
infants exposed to antipsychotics (including aripiprazole) during the third
trimester of pregnancy are at risk of adverse reactions including
extrapyramidal and/or withdrawal symptoms that may vary in severity and
duration following delivery. There have been reports of agitation, hypertonia,
hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.
Consequently, new-born infants should be monitored carefully (see
section&nbsp;4.8).</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Breast-feeding</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole
is excreted in human milk. A decision must be made whether to discontinue
breast-feeding or to discontinue/abstain from aripiprazole therapy taking into
account the benefit of breast feeding for the child and the benefit of therapy
for the woman.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Fertility</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p><span lang=EN-GB>Aripiprazole did not impair fertility based on data from
reproductive toxicity studies.</span></p>

<p><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.7     Effects on ability to
drive and use machines</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole
</span></em><span lang=EN-GB>has minor to moderate influence on the ability to
drive and use machines due to potential nervous system and visual effects, such
as sedation, somnolence, syncope, vision blurred, diplopia (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.8     Undesirable effects</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Summary
of the safety profile</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
most frequently observed adverse drug reactions (ADRs) reported in&nbsp;&#8805;&nbsp;5&nbsp;%
of patients in two double&#8209;blind, long-term trials of Abilify Maintena
were weight increased (9.0&nbsp;%), akathisia (7.9&nbsp;%), insomnia
(5.8&nbsp;%), and injection site pain (5.1&nbsp;%).</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Tabulated
list of adverse reactions</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The incidences of the ADRs associated with aripiprazole
therapy are tabulated below. The table is based on adverse reactions reported
during clinical trials and/or post-marketing use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>All ADRs are listed by system organ class and frequency;
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to&nbsp;&lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000 to&nbsp;&lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000 to&nbsp;&lt;&nbsp;1/1,000), very rare
(&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available
data). Within each frequency grouping, adverse reactions are presented in order
of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The frequency of adverse reactions reported during post-marketing
use cannot be determined as they are derived from spontaneous reports.
Consequently, the frequency of these adverse events is qualified as &quot;not
known&quot;.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:27.4pt'>
   <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Common</span></b></p>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Uncommon</span></b></p>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Blood and lymphatic system
  disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Neutropenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Thrombocytopenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Neutrophil count decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>White blood cell count decreased</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Leukopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Immune system disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypersensitivity</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Allergic reaction (e.g. anaphylactic
  reaction, angioedema including swollen tongue, tongue oedema, face oedema,
  pruritus, or urticaria)</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Endocrine disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood prolactin decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperprolactinaemia</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Diabetic hyperosmolar coma</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Diabetic ketoacidosis</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Weight increased</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diabetes mellitus</span></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Weight decreased</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperglycaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypercholesterolaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperinsulinaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperlipidaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertriglyceridaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Appetite disorder</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Anorexia</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Hyponatraemia</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Psychiatric disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Agitation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anxiety</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Restlessness</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Insomnia</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Suicidal ideation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Psychotic disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hallucination</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Delusion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypersexuality</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Panic reaction</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Depression</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Affect lability</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Apathy</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dysphoria</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sleep disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bruxism</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Libido decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Mood altered</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Completed suicide</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Suicide attempt</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Pathological gambling</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Impulse-control disorders</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Binge eating</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Compulsive shopping</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Poriomania</span></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Nervousness</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Aggression</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Extrapyramidal disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Akathisia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tremor</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dyskinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sedation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Somnolence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dizziness</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dystonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tardive dyskinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Parkinsonism</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Movement disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Psychomotor hyperactivity</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Restless legs syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Cogwheel rigidity</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bradykinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Drooling</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dysgeusia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Parosmia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Neuroleptic malignant syndrome</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Grand mal convulsion</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Serotonin syndrome</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Speech disorder</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Eye disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oculogyric crisis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vision blurred</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Eye pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diplopia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:black'>Photophobia</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Cardiac disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Ventricular extrasystoles</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bradycardia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tachycardia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Electrocardiogram T wave amplitude decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Electrocardiogram abnormal</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Electrocardiogram T wave inversion</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Sudden unexplained death</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Cardiac arrest</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Torsades de pointes</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Ventricular arrhythmias</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>QT prolongation</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Orthostatic hypotension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood pressure increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Syncope</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Venous thromboembolism (including
  pulmonary embolism and deep vein thrombosis)</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Respiratory, thoracic and
  mediastinal disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Cough</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hiccups</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Oropharyngeal spasm</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Laryngospasm</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Aspiration pneumonia</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dry mouth</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gastrooesophageal reflux disease</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dyspepsia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vomiting</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diarrhoea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nausea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Abdominal pain upper</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Abdominal discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Constipation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Frequent bowel movement</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Salivary hypersecretion</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Pancreatitis</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Dysphagia</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Hepatobiliary disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Liver function test abnormal Hepatic enzyme increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alanine aminotransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gamma-glutamyl transferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood bilirubin increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aspartate aminotransferase increased</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Hepatic failure</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Jaundice</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Hepatitis</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Alkaline phosphatase increased</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alopecia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Acne</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rosacea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Eczema</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Skin induration</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span style='color:black;
  font-style:normal'>Rash</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span style='color:black;
  font-style:normal'>Photosensitivity reaction</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span style='color:black;
  font-style:normal'>Hyperhidrosis</span></em></p>
  <p class=MsoNormal style='text-autospace:none'>Drug Reaction with
  Eosinophilia and Systemic Symptoms (DRESS)</p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Musculoskeletal and connective
  tissue disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Musculoskeletal stiffness</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Muscle rigidity</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Muscle spasms</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Muscle twitching</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Muscle tightness</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Myalgia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pain in extremity</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Arthralgia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Back pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Joint range of motion decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nuchal rigidity</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Trismus</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Rhabdomyolysis</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Renal and urinary disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nephrolithiasis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Glycosuria</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Urinary retention</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Urinary incontinence</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Pregnancy, puerperium and perinatal conditions</span></b></em></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Drug withdrawal syndrome neonatal (see
  section&nbsp;4.6)</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Reproductive system and breast
  disorders</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Erectile dysfunction</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Galactorrhoea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gynaecomastia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Breast tenderness</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vulvovaginal dryness</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Priapism</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>General disorders and
  administration site conditions</span></b></p>
  <p><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site induration Fatigue</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pyrexia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Asthenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gait disturbance</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Chest discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site reaction</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site erythema</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site swelling</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Injection site pruritus</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Thirst</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sluggishness </span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Temperature regulation disorder (e.g.
  hypothermia, pyrexia)</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Chest pain</span></em></p>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Peripheral oedema</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p><b><span lang=EN-GB style='color:black'>Investigations</span></b></p>
  <p><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood creatine phosphokinase increased</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Glycosylated haemoglobin increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Waist circumference increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood cholesterol decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood triglycerides decreased</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Blood glucose fluctuation</span></em></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Description
of selected adverse reactions</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Injection site
reactions</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>During
the double&#8209;blind, controlled phases of the two long-term trials,
injection site reactions were observed; those seen were generally mild to
moderate in severity, and resolved over time. </span></em><span lang=EN-GB>Injection
site pain (incidence 5.1&nbsp;%), had a median onset on day&nbsp;2 after the
injection and a median duration of 4&nbsp;days.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>In an open label study comparing
bioavailability of Abilify Maintena administered in the deltoid or gluteal
muscle, injection site related reactions were slightly more frequent in the
deltoid muscle. The majority were mild and improved on subsequent injections.
When compared to studies where Abilify Maintena was injected in the gluteal
muscle, repeated occurrence of injection site pain was more frequent in the
deltoid muscle.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><i><span lang=EN-GB>Leukopenia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Neutropenia has been reported in the
clinical program with <em><span style='color:black;font-style:normal'>Abilify
Maintena</span></em> and typically started around day&nbsp;16 after first
injection, and lasted a median of 18&nbsp;days.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Extrapyramidal
Symptoms (EPS)</span></em></p>

<p class=MsoNormal><span lang=EN-GB>In trials in stable patients with
schizophrenia, <em><span style='color:black;font-style:normal'>Abilify Maintena</span></em>
was associated with a higher frequency of EPS symptoms (18.4&nbsp;%) than oral
aripiprazole treatment (11.7&nbsp;%). Akathisia was the most frequently
observed symptom (8.2&nbsp;%) and typically started around day&nbsp;10 after
first injection, and lasted a median of 56&nbsp;days. Subjects with akathisia
typically received anti-cholinergic medicines as treatment, primarily
benzatropine mesilate and trihexyphenidyl. Less often substances such as
propranolol and benzodiazepines (clonazepam and diazepam) were administered to
control akathisia. Parkinsonism events followed in frequency of 6.9&nbsp;% for <em><span
style='color:black;font-style:normal'>Abilify Maintena</span></em>, 4.15&nbsp;%
for oral aripiprazole 10&#8209;30&nbsp;mg tablets and 3.0&nbsp;% for placebo,
respectively.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Dystonia</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Class
effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups,
may occur in susceptible individuals during the first few days of treatment.
Dystonic symptoms include spasm of the neck muscles, sometimes progressing to
tightness of the throat, swallowing difficulty, difficulty breathing, and/or
protrusion of the tongue. While these symptoms can occur at low doses, they
occur more frequently and with greater severity with high potency and at higher
doses of first generation antipsychotic medicinal products. An elevated risk of
acute dystonia is observed in males and younger age groups.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Weight</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>During
the Double-blind, Active-controlled Phase of the 38&#8209;week long-term trial,
the incidence of weight gain of </span></em><em><span lang=EN-GB
style='font-family:Symbol;color:black;font-style:normal'>³</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;7&nbsp;% from baseline
to last visit was 9.5&nbsp;% for Abilify Maintena and 11.7&nbsp;% for the oral
aripiprazole tablets 10&#8209;30&nbsp;mg. The incidence of weight loss of&nbsp;&#8805;&nbsp;7&nbsp;%
from baseline to last visit was 10.2&nbsp;% for Abilify Maintena and 4.5&nbsp;%
for oral aripiprazole tablets 10&#8209;30&nbsp;mg. During the Double-blind, Placebo-controlled
Phase of the 52&#8209;week long-term trial, the incidence of weight gain of </span></em><em><span
lang=EN-GB style='font-family:Symbol;color:black;font-style:normal'>³</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;7&nbsp;% from baseline
to last visit was 6.4&nbsp;% for Abilify Maintena and 5.2&nbsp;% for placebo. The
incidence of weight loss of&nbsp;&#8805;&nbsp;7&nbsp;% from baseline to last
visit was 6.4&nbsp;% for Abilify Maintena and 6.7&nbsp;% for placebo. During
double&#8209;blind treatment, mean change in body weight from baseline to last
visit was &#8209;0.2&nbsp;kg for Abilify Maintena and &#8209;0.4&nbsp;kg for
placebo (p&nbsp;=&nbsp;0.812).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><i><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Prolactin</span></i></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>In
clinical trials for the approved indications and post-marketing, both increase
and decrease in serum prolactin as compared to baseline was observed with
aripiprazole (section&nbsp;5.1).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Pathological gambling, hypersexuality,
compulsive shopping and binge or compulsive eating can occur in patients
treated with aripiprazole (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Reporting
of suspected adverse reactions</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via </span></em><span lang=EN-GB style='background:silver'>the
national reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span
style='background:silver'>Appendix V</span></u></a>.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.9     Overdose</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No cases of overdose associated with
adverse reactions were reported in clinical studies with <em><span
style='color:black;font-style:normal'>Abilify Maintena</span></em>. Care must
be taken to avoid inadvertent injection of this medicinal product into a blood
vessel. Following any confirmed or suspected accidental overdose/inadvertent
intravenous administration, close observation of the patient is needed and if
any potentially medically serious sign or symptom develops, monitoring, which
should include continuous electrocardiographic monitoring, is required. The
medical supervision and monitoring should continue until the patient recovers.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A simulation of dose dumping showed that
the predicted median aripiprazole concentration reaches a peak of 4,500&nbsp;ng/ml
or approximately&nbsp;9&nbsp;times the upper therapeutic range. In case of dose
dumping, aripiprazole concentrations are predicted to descend rapidly to the
upper limit of the therapeutic window after approximately&nbsp;3&nbsp;days. By
the 7th day, the median aripiprazole concentrations further decline to
concentrations following an IM depot dose with no dose dumping. <span
style='color:black'>While overdose is less likely with parenteral than oral
medicinal products, reference information for oral aripiprazole overdose is
presented below.</span></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Signs
and symptoms</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
clinical trials and post-marketing experience, accidental or intentional acute
overdose of aripiprazole alone was identified in adult patients with reported
estimated doses up to 1,260&nbsp;mg (41&nbsp;times highest recommended daily
aripiprazole dose) with no fatalities. The potentially medically important
signs and symptoms observed included lethargy, increased blood pressure,
somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports
of accidental overdose with aripiprazole alone (up to 195&nbsp;mg) in children
have been received with no fatalities. The potentially medically serious signs
and symptoms reported included somnolence, transient loss of consciousness and
extrapyramidal symptoms.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Management
of overdose</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Management
of overdose should concentrate on supportive therapy, maintaining an adequate
airway, oxygenation and ventilation, and management of symptoms. The
possibility of multiple medicinal product involvement should be considered.
Therefore, cardiovascular monitoring should be started immediately and should
include continuous electrocardiographic monitoring to detect possible arrhythmias.
Following any confirmed or suspected overdose with aripiprazole, close medical
supervision and monitoring should continue until the patient recovers.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Haemodialysis</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Although
there is no information on the effect of haemodialysis in treating an overdose
with aripiprazole, haemodialysis is unlikely to be useful in overdose
management since aripiprazole is highly bound to plasma proteins.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>5.       PHARMACOLOGICAL
PROPERTIES</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>5.1     Pharmacodynamic
properties</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Pharmacotherapeutic
group: Psycholeptics, other antipsychotics, ATC code: N05AX12</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Mechanism
of action</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>It
has been proposed that aripiprazoles efficacy in schizophrenia is mediated
through a combination of partial agonism at dopamine D<sub>2</sub> and
serotonin 5&#8209;HT<sub>1A</sub> receptors and antagonism at serotonin 5&#8209;HT<sub>2A</sub>
receptors. Aripiprazole exhibited antagonist properties in animal models of
dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity.
Aripiprazole exhibits high binding affinity </span></em><em><span lang=EN-GB
style='color:black'>in&nbsp;vitro</span></em><em><span lang=EN-GB
style='color:black;font-style:normal'> for dopamine D<sub>2</sub> and D<sub>3</sub>,
serotonin 5&#8209;HT<sub>1A</sub> and 5&#8209;HT<sub>2A</sub> receptors and has
moderate affinity for dopamine D<sub>4</sub>, serotonin 5&#8209;HT<sub>2C</sub>
and 5&#8209;HT<sub>7</sub>, alpha-1 adrenergic, and histamine H<sub>1</sub>
receptors. Aripiprazole also exhibited moderate binding affinity for the
serotonin reuptake site and no appreciable affinity for cholinergic muscarinic
receptors. Interaction with receptors other than dopamine and serotonin
subtypes may explain some of the other clinical effects of aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole
oral doses ranging from 0.5 to 30&nbsp;mg administered once a day to healthy
subjects for 2&nbsp;weeks produced a dose-dependent reduction in the binding of
<sup>11</sup>C&#8209;raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand,
to the caudate and putamen detected by positron emission tomography.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Clinical
efficacy and safety</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Maintenance
treatment of schizophrenia in adults</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
efficacy of Abilify Maintena in the maintenance treatment of patients with
schizophrenia was established in two randomised, double&#8209;blind, long-term trials.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
pivotal trial was a 38&nbsp;week, randomised, double&#8209;blind, active&#8209;controlled
trial designed to establish the efficacy, safety, and tolerability of this
medicinal product administered as monthly injections compared to once daily
oral aripiprazole tablets 10&#8209;30&nbsp;mg as maintenance treatment in adult
patients with schizophrenia. This trial consisted of a screening phase and
3&nbsp;treatment phases: Conversion Phase, Oral Stabilisation Phase, and
Double-blind, Active-controlled Phase.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Six-hundred
and sixty two patients eligible for the 38&#8209;week Double-blind, Active-controlled
Phase were randomly assigned in a 2:2:1 ratio to double&#8209;blind treatment
to one of 3&nbsp;treatment groups: 1) Abilify Maintena 2) the stabilisation
dose of oral aripiprazole 10&#8209;30&nbsp;mg, or 3) aripiprazole Long-Acting
Injectable&nbsp;50&nbsp;mg/25&nbsp;mg. The aripiprazole Long-Acting Injectable
50&nbsp;mg/25&nbsp;mg dose was included as a low dose aripiprazole to test
assay sensitivity for the non-inferiority design.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
results of analysis of the primary efficacy endpoint, the estimated proportion
of patients experiencing impending relapse by end of Week&nbsp;26 of the Double-blind,
Active-controlled Phase, showed that Abilify Maintena 400&nbsp;mg/300&nbsp;mg
is non-inferior to aripiprazole oral tablets 10&#8209;30&nbsp;mg.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
estimated relapse rate by end of Week&nbsp;26 was 7.12&nbsp;% for Abilify
Maintena, and 7.76&nbsp;% for oral aripiprazole tablets 10&#8209;30&nbsp;mg, a
difference of </span></em><em><span style='color:black;font-style:normal'>&#8722;</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>0.64&nbsp;%.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
95&nbsp;% CI (</span></em><em><span style='color:black;font-style:normal'>&#8722;</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>5.26, 3.99) for the difference
in the estimated proportion of patients experiencing impending relapse by end
of Week&nbsp;26 excluded the predefined non-inferiority margin, 11.5&nbsp;%.
Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10&#8209;30&nbsp;mg.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
estimated proportion of patients experiencing impending relapse by end of
Week&nbsp;26 for Abilify Maintena was 7.12&nbsp;%, which was statistically
significantly lower than in aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg
(21.80&nbsp;%; p&nbsp;=&nbsp;0.0006). Thus, superiority of Abilify Maintena
over the aripiprazole Long-Acting Injectable 50&nbsp;mg/25&nbsp;mg was
established and the validity of the trial design was confirmed.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
Kaplan-Meier curves of the time from randomisation to impending relapse during
the 38&#8209;week, Double-blind, Active-controlled Phase for Abilify Maintena,
oral aripiprazole 10&#8209;30&nbsp;mg, and aripiprazole Long-Acting Injectable
50&nbsp;mg/25&nbsp;mg are shown in Figure&nbsp;1.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>Figure&nbsp;1      Kaplan-Meier
Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending
Relapse</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB><img
border=0 width=535 height=334 id="Grafik 3207"
src="Abilify%20Maintena_clean_files/image001.png"></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-size:8.0pt;color:black;
font-style:normal'>NOTE: ARIP IMD 400/300&nbsp;mg&nbsp;=&nbsp;Abilify Maintena;ARIP
10&#8209;30&nbsp;mg&nbsp;=&nbsp;oral aripiprazole; ARIP IMD 50/25&nbsp;mg&nbsp;=&nbsp;Long-acting
Injectable</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Further,
the non-inferiority of Abilify Maintena compared to oral aripiprazole 10&#8209;30&nbsp;mg
is supported by the results of the analysis of the Positive and Negative
Syndrome Scale score (PANSS).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><em><b><span lang=EN-GB style='color:black;font-style:normal'>Table&nbsp;1       PANSS
Total Score  Change From Baseline to Week&nbsp;38-LOCF:<br>
Randomised Efficacy Sample<sup>a, b</sup></span></b></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='width:99.2%;margin-left:5.5pt;border-collapse:collapse;border:none'>
 <tr style='height:28.25pt'>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>PANSS Total Score  Change
  From Baseline to Week&nbsp;38-LOCF:</span></b></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>Randomised Efficacy Sample<sup>a,
  b</sup></span></b></em></p>
  </td>
 </tr>
 <tr style='height:38.85pt'>
  <td width="24%" valign=top style='width:24.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:38.85pt'>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="19%" valign=top style='width:19.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Abilify Maintena</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'> 400&nbsp;mg/300&nbsp;mg</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>(n&nbsp;=&nbsp;263)</span></em></p>
  </td>
  <td width="24%" valign=top style='width:24.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Oral aripiprazole</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>10&#8209;30&nbsp;mg/day</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>(n&nbsp;=&nbsp;266)</span></em></p>
  </td>
  <td width="30%" valign=top style='width:30.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Aripiprazole Long-Acting
  Injectable</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>50&nbsp;mg/25&nbsp;mg</span></em></p>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>(n&nbsp;=&nbsp;131)</span></em></p>
  </td>
 </tr>
 <tr style='height:16.55pt'>
  <td width="24%" valign=top style='width:24.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Mean baseline (SD)</span></b></em></p>
  </td>
  <td width="19%" valign=top style='width:19.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>57.9 (12.94)</span></em></p>
  </td>
  <td width="24%" valign=top style='width:24.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>56.6 (12.65)</span></em></p>
  </td>
  <td width="30%" valign=top style='width:30.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>56.1 (12.59)</span></em></p>
  </td>
 </tr>
 <tr style='height:16.55pt'>
  <td width="24%" valign=top style='width:24.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Mean change (SD)</span></b></em></p>
  </td>
  <td width="19%" valign=top style='width:19.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  style='color:black;font-style:normal'>&#8722;</span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'>1.8 (10.49)</span></em></p>
  </td>
  <td width="24%" valign=top style='width:24.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>0.7 (11.60)</span></em></p>
  </td>
  <td width="30%" valign=top style='width:30.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>3.2 (14.45)</span></em></p>
  </td>
 </tr>
 <tr style='height:12.7pt'>
  <td width="24%" valign=top style='width:24.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>P-value</span></b></em></p>
  </td>
  <td width="19%" valign=top style='width:19.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>NA</span></em></p>
  </td>
  <td width="24%" valign=top style='width:24.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>0.0272</span></em></p>
  </td>
  <td width="30%" valign=top style='width:30.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>0.0002</span></em></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><em><span
lang=EN-GB style='font-size:8.0pt;color:black;font-style:normal'>a:    Negative
change in score indicates improvement.</span></em></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><em><span
lang=EN-GB style='font-size:8.0pt;color:black;font-style:normal'>b:   Only
patients having both baseline and at least one post baseline were included.
P-values were derived from comparison for change from baseline within analysis
of covariance model with treatment as term and baseline as covariate.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
second trial was a 52&#8209;week, randomised, withdrawal, double&#8209;blind,
trial conducted in US adult patients with a current diagnosis of schizophrenia.
This trial consisted of a screening phase and 4&nbsp;treatment phases:
Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and
Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation
requirement in the Oral Stabilisation Phase were assigned to receive, in a
single-blind fashion, Abilify Maintena and began an Abilify Maintena
Stabilisation Phase for a minimum of 12&nbsp;weeks and a maximum of
36&nbsp;weeks. Patients eligible for the Double-blind, Placebo-controlled Phase
were randomly assigned in a 2:1 ratio to double&#8209;blind treatment with Abilify
Maintena or placebo, respectively.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
final efficacy analysis included 403 randomised patients and 80 exacerbations
of psychotic symptoms/impending relapse events. In the placebo group 39.6&nbsp;%
of the patients had progressed to impending relapse, whilst in the Abilify
Maintena group impending relapse occurred in 10&nbsp;% of the patients; thus
patients in the placebo group had a 5.03&#8209;fold greater risk of
experiencing impending relapse.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Prolactin</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
the Double-blind, Active-controlled Phase of the 38&#8209;week trial, from
baseline to last visit there was a mean decrease in prolactin levels in Abilify
Maintena (&#8722;0.33&nbsp;ng/ml) compared with a mean increase in oral
aripiprazole tablets 10&#8209;30&nbsp;mg (0.79&nbsp;ng/ml; p&nbsp;&lt;&nbsp;0.01).
The incidence of Abilify Maintena patients with prolactin levels&nbsp;&gt;&nbsp;1
time the upper limit of normal range (ULN) at any assessment was 5.4&nbsp;%
compared with 3.5&nbsp;% of the patients on oral aripiprazole tablets 10&#8209;30&nbsp;mg.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Male
patients generally had a higher incidence than female patients in each
treatment group.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
the Double-blind Placebo-controlled Phase of the 52&#8209;week trial, from
baseline to last visit there was a mean decrease in prolactin levels in Abilify
Maintena (&#8722;0.38&nbsp;ng/ml) compared with a mean increase in placebo
(1.67&nbsp;ng/ml). The incidences of Abilify Maintena patients with prolactin
levels&nbsp;&gt;&nbsp;1 time the upper limit of normal range (ULN) was
1.9&nbsp;% compared to 7.1&nbsp;% for placebo patients.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><i><span lang=EN-GB>Acute treatment of schizophrenia in
adults</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of Abilify Maintena in acutely
relapsed adult patients with schizophrenia was established in a short-term
(12-week), randomised, double&#8209;blind, placebo-controlled trial
(n&nbsp;=&nbsp;339).</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint (change in PANSS total
score from baseline to week&nbsp;10) showed superiority of Abilify Maintena
(n&nbsp;=&nbsp;167) over placebo (n&nbsp;=&nbsp;172).</span></p>

<p class=MsoNormal><span lang=EN-GB>Similar to the PANSS Total Score, both the
PANSS positive and negative subscale scores also showed an improvement
(decrease) from baseline over time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB style='color:black'>Table&nbsp;2       PANSS Total
Score  Change From Baseline to week&nbsp;10: Randomised Efficacy Sample</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=612 colspan=3 valign=top style='width:458.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>PANSS Total Score  Change
  From Baseline to Week&nbsp;10:</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>Randomised Efficacy Sample <sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=255 valign=top style='width:191.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><sup><span lang=EN-GB>&nbsp;</span></sup></b></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Abilify Maintena</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>400&nbsp;mg/300&nbsp;mg</span></b></p>
  </td>
  <td width=177 valign=top style='width:132.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Placebo</span></b></p>
  <p class=MsoNormal><b><sup><span lang=EN-GB>&nbsp;</span></sup></b></p>
  </td>
 </tr>
 <tr>
  <td width=255 valign=top style='width:191.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Mean baseline (SD)</span></b></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center'><span
  lang=EN-GB>102.4 (11.4)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;162</span></p>
  </td>
  <td width=177 valign=top style='width:132.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center'><span
  lang=EN-GB>103.4 (11.1)</span></p>
  <p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center'><span
  lang=EN-GB>n&nbsp;=&nbsp;167</span></p>
  </td>
 </tr>
 <tr>
  <td width=255 valign=top style='width:191.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>LS Mean change
  (SE)</span></b></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center'><em><span
  style='color:black;font-style:normal'>&#8722;</span></em><span lang=EN-GB>26.8
  (1.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;99</span></p>
  </td>
  <td width=177 valign=top style='width:132.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center'><em><span
  style='color:black;font-style:normal'>&#8722;</span></em><span lang=EN-GB>11.7
  (1.6)</span></p>
  <p class=MsoNormal align=center style='margin-right:5.65pt;text-align:center'><span
  lang=EN-GB>n&nbsp;=&nbsp;81</span></p>
  </td>
 </tr>
 <tr>
  <td width=255 valign=top style='width:191.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>P-value</span></b></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width=177 valign=top style='width:132.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><sup><span lang=EN-GB>&nbsp;</span></sup></b></p>
  </td>
 </tr>
 <tr style='height:3.2pt'>
  <td width=255 valign=top style='width:191.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Treatment difference<sup>b</sup>
  (95&nbsp;% CI)</span></b></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  style='color:black;font-style:normal'>&#8722;</span></em><span lang=EN-GB>15.1
  (</span><em><span style='color:black;font-style:normal'>&#8722;</span></em><span
  lang=EN-GB>19.4, </span><em><span style='color:black;font-style:normal'>&#8722;</span></em><span
  lang=EN-GB>10.8)</span></p>
  </td>
  <td width=177 valign=top style='width:132.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal><b><sup><span lang=EN-GB>&nbsp;</span></sup></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
lang=EN-GB style='font-size:8.0pt'>a        </span></sup><span lang=EN-GB
style='font-size:8.0pt'>Data were analysed using a mixed model repeated
measures (MMRM) approach. The analysis included only subjects who were randomly
assigned to treatment, given at least one injection, had baseline and at least
one post-baseline efficacy assessment.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
lang=EN-GB style='font-size:8.0pt'>b        </span></sup><span lang=EN-GB
style='font-size:8.0pt'>Difference (Abilify Maintena minus placebo) in least
squares mean change from baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Abilify Maintena also showed statistically
significant improvement in symptoms represented by CGIS score change from
baseline to week&nbsp;10.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Personal and social functioning were
evaluated using the Personal and Social Performance (PSP) scale. The PSP is a
validated clinician-rated scale that measures personal and social functioning
in four domains: socially useful activities (e.g. work and study), personal and
social relationships, self-care, and disturbing and aggressive behaviours.
There was a statistically significant treatment difference in favour of Abilify
Maintena 400&nbsp;mg/300&nbsp;mg compared to placebo at week&nbsp;10 (+7.1,
p&nbsp;&lt;&nbsp;0.0001, 95&nbsp;% CI: 4.1, 10.1 using an ANCOVA model (LOCF)).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The safety profile was
consistent with that known to Abilify Maintena. Nevertheless, there were
differences from what has been observed with maintenance use in the treatment
of schizophrenia. In </span><span lang=EN-GB>a short-term (12-week),
randomised, double&#8209;blind, placebo-controlled trial with <span
style='color:black'>Abilify Maintena 400</span>&nbsp;<span style='color:black'>mg/300</span>&nbsp;<span
style='color:black'>mg treated subjects the symptoms which had at least twice
the incidence of placebo were increased weight and akathisia. The incidence of
weight gain of&nbsp;&#8805;&nbsp;7&nbsp;% from baseline to last visit (week</span>&nbsp;<span
style='color:black'>12) was 21.5&nbsp;% for Abilify Maintena compared with the
placebo group 8.5&nbsp;%. Akathisia was the most frequently observed EPS
symptom (Abilify Maintena 11.4</span>&nbsp;<span style='color:black'>% and
placebo group 3.5&nbsp;%).</span></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Paediatric
population</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
European Medicines Agency has waived the obligation to submit the results of
studies with Abilify Maintena in all subsets of the paediatric population in
schizophrenia (see section&nbsp;4.2).</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>5.2     Pharmacokinetic
properties</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Absorption</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole
absorption into the systemic circulation is slow and prolonged following Abilify
Maintena administration due to low solubility of aripiprazole particles.</span></em><span
lang=EN-GB>The <span style='color:black'>average absorption half-life of <em><span
style='font-style:normal'>Abilify Maintena</span></em> is 28&nbsp;days.<em><span
style='font-style:normal'> </span></em></span>Absorption of aripiprazole from
the IM depot formulation was complete relative to the IM standard
(immediate-release) formulation<span style='color:black'>. The dose adjusted C<sub>max</sub>
values for the depot formulation were approximately&nbsp;5<em><span
style='font-style:normal'>&nbsp;</span></em>% of C<sub>max</sub> from IM
standard formulation.</span>Following a single dose administration of Abilify
Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was
similar for both injection sites, but the rate of absorption (C<sub>max</sub>)
was higher following administration to the deltoid muscle. Following multiple
intramuscular doses, the plasma concentrations of aripiprazole gradually rise
to a maximum&nbsp;plasma concentration at a median t<sub>max </sub>of&nbsp;7&nbsp;days
for the gluteal muscle and 4&nbsp;days for the deltoid muscle. Steady state
concentrations for the typical subject were attained by the fourth dose for
both sites of administration. <em><span style='color:black;font-style:normal'>Less
than dose-proportional increases in aripiprazole and dehydro-aripiprazole
concentrations and AUC parameters are observed after monthly Abilify Maintena
injections of 300&nbsp;mg to 400&nbsp;mg.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Distribution</span></u></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Based
on results from trials with oral administration of aripiprazole, aripiprazole
is widely distributed throughout the body with an apparent volume of
distribution of 4.9&nbsp;l/kg, indicating extensive extravascular distribution.
At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are
greater than 99&nbsp;% bound to serum proteins, binding primarily to albumin.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Biotransformation</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Aripiprazole
is extensively metabolised by the liver primarily by three biotransformation pathways:
dehydrogenation, hydroxylation, and N-dealkylation. Based on </span></em><em><span
lang=EN-GB style='color:black'>in&nbsp;vitro</span></em><em><span lang=EN-GB
style='color:black;font-style:normal'> studies, CYP3A4 and CYP2D6 enzymes are
responsible for dehydrogenation and hydroxylation of aripiprazole, and
N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal
product moiety in systemic circulation. After multiple dose administration of Abilify
Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1&#8209;32.5&nbsp;%
of aripiprazole AUC in plasma.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Elimination</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>After
administration of multiple dose of 400&nbsp;mg or 300&nbsp;mg of Abilify
Maintena, the mean aripiprazole terminal elimination half-life is respectively
46.5 and 29.9&nbsp;days </span></em><span lang=EN-GB style='color:black'>presumably
due to absorption rate-limited kinetics.<em><span style='font-style:normal'> Following
a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately&nbsp;27&nbsp;%
of the administered radioactivity was recovered in the urine and approximately&nbsp;60&nbsp;%
in the faeces. Less than 1&nbsp;% of unchanged aripiprazole was excreted in the
urine and approximately&nbsp;18&nbsp;% was recovered unchanged in the faeces.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Pharmacokinetics
in special patient groups</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>CYP2D6 poor
metabolisers</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Based
on population pharmacokinetic evaluation of Abilify Maintena, the total body
clearance of aripiprazole was 3.71&nbsp;L/h in extensive metabolisers of CYP2D6
and approximately&nbsp;1.88&nbsp;L/h (approximately&nbsp;50&nbsp;% lower) in
poor metabolisers of CYP2D6 (for dose recommendation, see section&nbsp;4.2).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Elderly</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>After
oral administration of aripiprazole, there are no differences in the
pharmacokinetics of aripiprazole between healthy elderly and younger adult
subjects. Similarly, there was no detectable effect of age in a population
pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Gender</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>After
oral administration of aripiprazole, there are no differences in the
pharmacokinetics of aripiprazole between healthy male and female subjects.
Similarly, there was no clinically relevant effect of gender in a population
pharmacokinetic analysis of Abilify Maintena in clinical trials in patients
with schizophrenia.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Smoking</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Population
pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of
clinically relevant effects from smoking on the pharmacokinetics of
aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Race</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Population
pharmacokinetic evaluation showed no evidence of race-related differences on
the pharmacokinetics of aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Renal impairment</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
a single-dose study with oral administration of aripiprazole, the
pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were
found to be similar in patients with severe renal disease compared to that in young
healthy subjects.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Hepatic impairment</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>A
single-dose study with oral administration of aripiprazole to subjects with
varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not
reveal a significant effect of hepatic impairment on the pharmacokinetics of
aripiprazole and dehydro-aripiprazole, but the study included only
3&nbsp;patients with Class C liver cirrhosis, which is insufficient to draw
conclusions on their metabolic capacity.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>5.3     Preclinical safety
data</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
toxicological profile for aripiprazole administered to experimental animals by
intramuscular injection is generally similar to that seen following oral
administration at comparable plasma levels. With intramuscular injection,
however </span></em><span lang=EN-GB style='color:black'>an inflammatory
response was seen at the injection site, and consisted of granulomatous
inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling)
and, in monkeys, fibrosis. <em><span style='font-style:normal'>These effects
gradually resolved with discontinuation of dosing.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Non-clinical
safety data for orally administered aripiprazole reveal no special hazard for
humans based on conventional studies of safety pharmacology, repeated dose
toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and
development.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Oral
aripiprazole</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>For
oral aripiprazole, toxicologically significant effects were observed only at
doses or exposures that were sufficiently in excess of the maximum human dose
or exposure, indicating that these effects were limited or of no relevance to
clinical use. These included: dose-dependent adrenocortical toxicity in rats
after 104&nbsp;weeks of oral administration at approximately&nbsp;3 to
10&nbsp;times the mean steady-state AUC at the maximum recommended human dose
and increased adrenocortical carcinomas and combined adrenocortical
adenomas/carcinomas in female rats at approximately&nbsp;10&nbsp;times the mean
steady-state AUC at the maximum recommended human dose. The highest
non-tumorigenic exposure in female rats was approximately&nbsp;7&nbsp;times the
human exposure at the recommended dose.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>An
additional finding was cholelithiasis as a consequence of precipitation of
sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of
monkeys after repeated oral dosing at 25 to 125&nbsp;mg/kg/day or
approximately16 to 81&nbsp;times the maximum recommended human dose based on
mg/m<sup>2</sup>.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>However,
the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human
bile at the highest dose proposed, 30&nbsp;mg per day, were no more than
6&nbsp;% of the bile concentrations found in the monkeys in the 39&#8209;week
study and are well below (6&nbsp;%) their limits of </span></em><em><span
lang=EN-GB style='color:black'>in&nbsp;vitro</span></em><em><span lang=EN-GB
style='color:black;font-style:normal'> solubility.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>In
repeated dose studies in juvenile rats and dogs, the toxicity profile of
aripiprazole was comparable to that observed in adult animals, and there was no
evidence of neurotoxicity or adverse events on development.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Based
on results of a full range of standard genotoxicity tests, aripiprazole was
considered non-genotoxic. Aripiprazole did not impair fertility in reproductive
toxicity studies.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Developmental
toxicity, including dose-dependent delayed foetal ossification and possible
teratogenic effects, were observed in rats at doses resulting in
sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in
exposures approximately&nbsp;3 and 11&nbsp;times the mean steady-state AUC at
the maximum recommended clinical dose. Maternal toxicity occurred at doses
similar to those eliciting developmental toxicity.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.       PHARMACEUTICAL
PARTICULARS</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.1     List of excipients</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Powder</span></u></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Carmellose
sodium</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Mannitol</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Sodium
dihydrogen phosphate monohydrate</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Sodium
hydroxide</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Solvent</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Water
for injections</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.2     Incompatibilities</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Not
applicable</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.3     Shelf life</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>3&nbsp;years</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Abilify Maintena
powder and solvent for prolonged-release suspension for injection</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
suspension should be injected immediately after reconstitution but can be stored
below 25&nbsp;°C for up to 4&nbsp;hours in the vial.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Abilify Maintena
powder and solvent for prolonged-release suspension for injection in pre&#8209;filled&nbsp;syringe</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
suspension should be injected immediately after reconstitution but can be
stored below 25&nbsp;°C for up to 2&nbsp;hours in the syringe.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>After reconstitution</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Chemical and physical in-use stability has
been demonstrated for 4&nbsp;hours at 25&nbsp;°C. From a microbiological point
of view, unless the method of opening/ reconstitution precludes the risk of
microbial contamination, the product should be used immediately. If not used
immediately, in-use storage times and conditions are the responsibility of
user. Do not store the reconstituted suspension in the syringe.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below 25&nbsp;°C
for up to 2&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.4     Special precautions
for storage</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not freeze.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the syringe in the outer carton in
order to protect from light.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions after reconstitution
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.5     Nature and contents of
container</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Vial</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Type&#8209;I
glass vial stoppered with a laminated rubber stopper and sealed with a flip-off
aluminium cap.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Solvent</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>2&nbsp;ml
Type&#8209;1 glass vial stoppered with a laminated rubber stopper and sealed
with a flip-off aluminium cap.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Single pack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
single pack containing one vial of powder, 2&nbsp;ml vial of solvent, one
3&nbsp;ml luer lock syringe with pre-attached 38&nbsp;mm (1.5&nbsp;inch)
21&nbsp;gauge, hypodermic safety needle with needle protection device, one
3&nbsp;ml disposable syringe with luer lock tip, one vial adapter and three
hypodermic safety needles: one 25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge, one
38&nbsp;mm (1.5&nbsp;inch) 22&nbsp;gauge and one 51&nbsp;mm (2&nbsp;inch)
21&nbsp;gauge.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Multipack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Bundle
pack of 3&nbsp;single packs.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled&nbsp;syringe</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled&nbsp;syringe</span></u></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Clear glass
pre-filled syringe (type-I glass) with grey chlorobutyl stoppers (front-,
middle- and end stopper), polypropylene front assembly, polypropylene finger
grip, plunger rod, and silicone over-cap. The front chamber between front
stopper and middle stopper contains the powder and the rear chamber between
middle stopper and end stopper the solvent.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Single pack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
single pack containing one pre&#8209;filled syringe, and three hypodermic
safety needles: one 25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge, one 38&nbsp;mm
(1.5&nbsp;inch) 22&nbsp;gauge and one 51&nbsp;mm (2&nbsp;inch) 21&nbsp;gauge.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Multipack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Bundle
pack of 3&nbsp;single packs.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Not
all pack sizes may be marketed.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.6     Special precautions
for disposal and other handling</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Abilify Maintena 300&nbsp;mg powder and
solvent for prolonged-release suspension for injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Abilify Maintena 400&nbsp;mg powder and
solvent for prolonged-release suspension for injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the
syringe vigorously for 20&nbsp;seconds until medicine is uniformly milky-white
and use immediately. If the injection is not performed immediately after
reconstitution, the syringe can be kept below 25&nbsp;°C for up to 2&nbsp;hours.
Shake the syringe vigorously for at least 20&nbsp;seconds to re&#8209;suspend
prior to injection if the syringe has been left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Gluteal muscle
administration</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>The recommended needle for gluteal
administration is a 38&nbsp;mm (1.5&nbsp;inch), 22&nbsp;gauge hypodermic safety
needle; for obese patients (Body mass index&nbsp;&gt;&nbsp;28&nbsp;kg/m<sup>2</sup>),
a 51&nbsp;mm (2&nbsp;inch), 21&nbsp;gauge hypodermic safety needle should be
used. </span></em><span lang=EN-GB>Gluteal injections should be alternated
between the two gluteal muscles.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Deltoid muscle
administration</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>The recommended
needle for deltoid administration is a 25&nbsp;mm (1&nbsp;inch), 23&nbsp;gauge
hypodermic safety needle; for obese patients, a 38&nbsp;mm (1.5&nbsp;inch),
22&nbsp;gauge hypodermic safety needle should be used.</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Deltoid
injections should be alternated between the two deltoid muscles.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
powder and solvent vials and the pre&#8209;filled&nbsp;syringe are for
single-use only.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Any
unused medicinal product or waste material should be disposed of in accordance
with local requirements.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Full instructions for
use and handling of Abilify Maintena are provided in the package leaflet
(information intended for healthcare professionals).</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>7.       MARKETING
AUTHORISATION HOLDER</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>8.       MARKETING
AUTHORISATION NUMBER(S)</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/001</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/003</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/002</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/004</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/005</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/007</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled&nbsp;syringe</span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/006</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/008</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Date
of first authorisation: 15 November 2013</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Date
of latest renewal: 27 August 2018</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>10.     DATE OF REVISION OF
THE TEXT</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>MM/YYYY</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><u>http://www.ema.europa.eu</u></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
text-autospace:none'><b><span lang=EN-GB style='color:black'>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>A.      MANUFACTURER RESPONSIBLE
FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>B.      CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>C.      OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB style='color:black'>D.      CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.      MANUFACTURER RESPONSIBLE FOR BATCH
RELEASE</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><u><span
lang=EN-GB>Name and address of the manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>H. Lundbeck A/S</span></p>

<p class=MsoNormal><span lang=EN-GB>Ottiliavej 9</span></p>

<p class=MsoNormal><span lang=EN-GB>DK<span style='color:black'> </span>2500
Valby</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Denmark</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>Elaiapharm</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2881 Route des
Crêtes Z.I Les Bouillides Sophia Antipolis</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>06550 Valbonne</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>France</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=TitleB><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF
THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:6.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>        Periodic <span style='color:black'>safety
update reports</span></span></b><b><span lang=EN-GB style='color:black'> (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The requirements for submission of </span><span
lang=EN-GB>PSURs</span><span lang=EN-GB> for this medicinal product are set out
in the list of Union reference dates (EURD list) provided for under Article
107c(7) of Directive 2001/83/EC and any subsequent updates published on the
European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:34.35pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:34.35pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>        Risk </span></b><b><span lang=EN-GB>management
plan</span></b><b><span lang=EN-GB> (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>The </span><span lang=EN-GB>marketing authorisation holder (</span><span
lang=EN-GB>MAH</span><span lang=EN-GB>)</span><span lang=EN-GB> shall perform
the required pharmacovigilance activities and interventions detailed in the
agreed RMP presented in Module<span style='color:black'>&nbsp;</span>1.8.2 of
the </span><span lang=EN-GB>marketing authorisation</span><span lang=EN-GB> and
any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>        </span></b><span lang=EN-GB>At the request
of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>        </span></b><span lang=EN-GB>Whenever the
risk management system is modified, especially as the result of new information
being received that may lead to a significant change to the benefit/risk
profile or as the result of an important (pharmacovigilance or risk
minimisation) milestone being reached.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center;
text-autospace:none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>ANNEX&nbsp;III</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>LABELLING AND PACKAGE LEAFLET</span></b></em></p>

<em><b><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></b></em>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=TitleA><span lang=EN-GB>A.&nbsp;LABELLING</span></p>

<em><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></em>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Outer carton - Single pack 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
300&nbsp;mg aripiprazole. After reconstitution each ml of suspension contains
200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of powder</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of 2&nbsp;ml solvent</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Two sterile syringes, one with needle for reconstitution</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One vial adapter</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Shelf-life after
reconstitution: 4&nbsp;hours below 25&nbsp;°C</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not store the
reconstituted suspension in the syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/001</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Outer label (with blue box) - Multipack 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
300&nbsp;mg aripiprazole.After reconstitution each ml of suspension contains
200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Multipack: Three single packages, each containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of powder</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of 2&nbsp;ml solvent</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Two sterile syringes, one with needle for reconstitution</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One vial adapter</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL WARNING(S),
IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Shelf-life after
reconstitution: 4&nbsp;hours below 25&nbsp;°C</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not store the
reconstituted suspension in the syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/003</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Carton (without blue box)  component of
multipack 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></p>

<p class=MsoNormal>aripiprazole</p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 300&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL FORM
AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Single package containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of powder</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of 2&nbsp;ml solvent</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Two sterile syringes, one with needle for reconstitution</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One vial adapter</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Shelf-life after
reconstitution: 4&nbsp;hours below 25&nbsp;°C</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not store the reconstituted
suspension in the syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/003</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Vial powder 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder for prolonged-release injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>IM</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>300&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Outer carton - Single pack 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
400&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of powder</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of 2&nbsp;ml solvent</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Two sterile syringes, one with needle for reconstitution</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One vial adapter</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Shelf-life after
reconstitution: 4&nbsp;hours below 25&nbsp;°C</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not store the reconstituted
suspension in the syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/002</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Outer label (with blue box) - Multipack 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
400&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Multipack: Three single packages, each containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of powder</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of 2&nbsp;ml solvent</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Two sterile syringes, one with needle for reconstitution</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One vial adapter</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Shelf-life after
reconstitution: 4&nbsp;hours below 25&nbsp;°C</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not store the
reconstituted suspension in the syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/004</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Carton (without blue box)  component of
multipack 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection</span></p>

<p class=MsoNormal>aripiprazole</p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
400&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml</span><span lang=EN-GB> of suspension contains 200&nbsp;mg
aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Single package containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of powder</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One vial of 2&nbsp;ml solvent</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Two sterile syringes, one with needle for reconstitution</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One vial adapter</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Shake the vial vigorously for at least
30&nbsp;seconds until the suspension appears uniform.</span></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution shake it vigorously for at least
60&nbsp;seconds to re&#8209;suspend prior to injection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Shelf-life after
reconstitution: 4&nbsp;hours below 25&nbsp;°C</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not store the
reconstituted suspension in the syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard vial, adapter,
syringe, needles, unused suspension and water for injections appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/004</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Vial Powder 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder for prolonged-release injection</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>IM</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>400&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Vial solvent</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Solvent for Abilify
Maintena</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>2&nbsp;ml</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Outer carton - Single pack 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled syringe</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each pre&#8209;filled
syringe contains 300&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One</span><span lang=EN-GB> pre&#8209;filled syringe
containing powder in the front chamber and solvent in the rear chamber.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the
syringe vigorously for 20&nbsp;seconds until medicine is uniformly milky-white
and use immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below 25&nbsp;°C
for up to 2&nbsp;hours. Shake the syringe vigorously for at least
20&nbsp;seconds to re&#8209;suspend prior to injection if the syringe has been
left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Keep the pre&#8209;filled syringe
in the outer carton in order to protect from light.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard pre&#8209;filled
syringe and needles appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/005</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Outer label (with blue box) - Multipack 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled syringe</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each pre&#8209;filled
syringe contains 300&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Multipack: Three single packages, each containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One </span><span lang=EN-GB>pre<span style='color:black'>&#8209;</span>filled
syringe containing powder in the front chamber and solvent in the rear chamber.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the
syringe vigorously for 20&nbsp;seconds until medicine is uniformly milky-white
and use immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below
25&nbsp;°C for up to 2&nbsp;hours. Shake the syringe vigorously for at least
20&nbsp;seconds to re&#8209;suspend prior to injection if the syringe has been
left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Keep the pre&#8209;filled syringe
in the outer carton in order to protect from light.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard pre</span><span
lang=EN-GB>&#8209;<span style='color:black'>filled syringe and needles
appropriately.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/007</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Carton (without blue box)  component of
multipack 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled syringe</span></p>

<p class=MsoNormal>aripiprazole</p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Each pre&#8209;filled syringe contains
300&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Single package containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One </span><span lang=EN-GB>pre&#8209;filled syringe
containing powder in the front chamber and solvent in the rear chamber.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the
syringe vigorously for 20&nbsp;seconds until medicine is uniformly milky-white
and use immediately.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below
25&nbsp;°C for up to 2&nbsp;hours. Shake the syringe vigorously for at least
20&nbsp;seconds to re&#8209;suspend prior to injection if the syringe has been
left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Keep the pre&#8209;filled syringe
in the outer carton in order to protect from light.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard pre</span><span
lang=EN-GB>&#8209;<span style='color:black'>filled syringe and needles appropriately.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/007</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='text-autospace:none;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Pre&#8209;filled syringe - 300&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
300&nbsp;mg injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>IM</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>300&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Outer carton - Single pack 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled syringe</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each pre&#8209;filled
syringe contains 400&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One</span><span
lang=EN-GB> pre<span style='color:black'>&#8209;</span>filled syringe
containing powder in the front chamber and solvent in the rear chamber.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Three hypodermic safety
needles</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the
syringe vigorously for 20&nbsp;seconds until medicine is uniformly milky-white
and use immediately.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL WARNING(S),
IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below
25&nbsp;°C for up to 2&nbsp;hours. Shake the syringe vigorously for at least
20&nbsp;seconds to re&#8209;suspend prior to injection if the syringe has been
left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the pre&#8209;filled syringe in the
outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard pre</span><span
lang=EN-GB>&#8209;<span style='color:black'>filled syringe and needles
appropriately.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/006</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Outer label (with blue box) - Multipack
400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre&#8209;filled syringe</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each pre&#8209;filled
syringe contains 400&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml of suspension contains 200&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Multipack: Three single packages, each containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One </span><span lang=EN-GB>pre<span style='color:black'>&#8209;</span>filled
syringe containing powder in the front chamber and solvent in the rear chamber.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Three hypodermic safety needles</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the syringe
vigorously for 20&nbsp;seconds until medicine is uniformly milky-white and use
immediately.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below
25&nbsp;°C for up to 2&nbsp;hours. Shake the syringe vigorously for at least
20&nbsp;seconds to re&#8209;suspend prior to injection if the syringe has been
left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the pre&#8209;filled syringe in the
outer carton in order to protect from light.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard pre</span><span
lang=EN-GB>&#8209;<span style='color:black'>filled syringe and needles appropriately.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/008</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>Carton (without blue box)  component of
multipack 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg powder and solvent for prolonged-release suspension for injection
in pre</span><span lang=EN-GB>&#8209;<span style='color:black'>filled syringe</span></span></p>

<p class=MsoNormal>aripiprazole</p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each pre&#8209;filled
syringe contains 400&nbsp;mg aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>After reconstitution
each ml</span><span lang=EN-GB> of suspension contains 200&nbsp;mg
aripiprazole.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Powder</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Carmellose sodium,
mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Solvent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Powder and solvent for prolonged-release
suspension for injection</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Single package containing:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>One </span><span lang=EN-GB>pre<span style='color:black'>&#8209;</span>filled
syringe containing powder in the front chamber and solvent in the rear chamber.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Three hypodermic safety
needles</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Component of a multipack, cant be sold
separately.</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Intramuscular use only</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Vertically shake the
syringe vigorously for 20&nbsp;seconds until medicine is uniformly milky-white
and use immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       SPECIAL WARNING THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If the injection is not
performed immediately after reconstitution, the syringe can be kept below
25&nbsp;°C for up to 2&nbsp;hours. Shake the syringe vigorously for at least
20&nbsp;seconds to re&#8209;suspend prior to injection if the syringe has been
left for more than 15&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the pre&#8209;filled syringe in the
outer carton in order to protect from light.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Discard pre</span><span
lang=EN-GB>&#8209;<span style='color:black'>filled syringe and needles appropriately.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>11.     NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/13/882/008</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>15.     INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:silver'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>Pre&#8209;filled syringe - 400&nbsp;mg</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena
400&nbsp;mg injection</span></p>

<p class=MsoNormal><span style='color:black'>aripiprazole</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>IM</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>2.       METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>5.       CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>400&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<em><b><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></b></em>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=TitleA><span lang=EN-GB>B.&nbsp;PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<em><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></em>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>Package leaflet: Information
for the user</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='color:black'>Abilify Maintena <em><span style='font-style:normal'>300&nbsp;mg
powder and solvent for prolonged-release suspension for injection</span></em></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='color:black'>Abilify Maintena <em><span style='font-style:normal'>400&nbsp;mg
powder and solvent for prolonged-release suspension for injection</span></em></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><em><span lang=EN-GB
style='color:black;font-style:normal'>aripiprazole</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Read
all of this leaflet carefully before you receive this medicine because it
contains important information for you.</span></b></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Keep this leaflet.
You may need to read it again.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        If you have any
further questions, ask your doctor or nurse.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        If you get any side
effects, talk to your doctor or nurse. This includes any possible side effects
not listed in this leaflet. See section&nbsp;4.</span></em></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>What is in this leaflet</span></b></em></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>1.       What </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is and what it is used for</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>2.       What you need to know
before you are given </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>3.       How </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is given</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>4.       Possible side effects</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>5.       How to store </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>6.       Contents of the pack
and other information</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>1.       What </span></b></em><b><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is and what it is used for</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>contains the active substance aripiprazole and
belongs to a group of medicines called antipsychotics. It is used to treat
schizophrenia - a disease with symptoms such as hearing, seeing or sensing
things which are not there, suspiciousness, mistaken beliefs, incoherent speech
and behaviour and emotional flatness. People with this condition may also feel
depressed, guilty, anxious or tense.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>is intended for adult patients with schizophrenia who
are sufficiently stabilised during treatment with oral aripiprazole.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>2.       What you need to know
before you are given </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Do
not use </span></b></em><b><span lang=EN-GB style='color:black'>Abilify Maintena</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'></span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>        if you are allergic to
aripiprazole or any of the other ingredients of this medicine (listed in
section&nbsp;6).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Warnings
and precautions</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Talk
to your doctor or nurse before you are given </span></em><span lang=EN-GB
style='color:black'>Abilify Maintena<em><span style='font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Suicidal
thoughts and behaviours have been reported during aripiprazole treatment. Tell
your doctor immediately if you are having any thoughts or feelings about
hurting yourself.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Before
treatment with </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena<em><span style='font-style:normal'>, tell your doctor if you suffer
from</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        an acutely agitated
state or a severely psychotic state</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        heart problems or
have a history of stroke, especially if you know that you have other risks
factors for stroke</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        high blood sugar
(characterised by symptoms such as excessive thirst, passing of large amounts
of urine, increase in appetite and feeling weak) or family history of diabetes</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        fits (seizures) since
your doctor may want to monitor you more closely</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        involuntary,
irregular muscle movements, especially in the face</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>experience a combination of fever, sweating,
faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs
of neuroleptic malignant syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dementia (loss of memory and other mental
abilities) especially if you are elderly</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        cardiovascular
diseases (diseases of the heart and circulation), family history of
cardiovascular disease, stroke or &quot;mini&quot; stroke, abnormal blood
pressure</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        irregular heart beat
or if someone else in your family has a history of irregular heart beat
(including so called QT prolongation seen with ECG monitoring).</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        blood clots, or family
history of blood clots, as antipsychotics have been associated with formation
of blood clots</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>have any difficulty in swallowing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        past experience with
excessive gambling</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        severe liver
problems.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you notice you are gaining weight, develop unusual movements, experience
sleepiness that interferes with normal daily activities, any difficulty in swallowing
or have allergic symptoms, please talk to your doctor immediately.</span></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor if you or your
family/carer notices that you are developing urges or cravings to behave in
ways that are unusual for you and you cannot resist the impulse, drive or
temptation to carry out certain activities that could harm yourself or others.
These are called impulse control disorders and can include behaviours such as
addictive gambling, excessive eating or spending, an abnormally high sex drive
or preoccupation with an increase in sexual thoughts or feelings.</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Your doctor may need to adjust or stop
your dose.</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Aripiprazole may cause sleepiness, fall in
blood pressure when standing up, dizziness and changes in your ability to move
and balance, which may lead to falls. Caution should be taken, particularly if
you are an elderly patient or have some debility.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not use this
medicine in children and adolescents under 18&nbsp;years of age. It is not
known if it is safe and effective in these patients.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Other
medicines and </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tell
your doctor if you are taking, have recently taken or might take any other
medicines.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Blood
pressure-lowering medicines:</span></em><span lang=EN-GB style='color:black'>
Abilify Maintena <em><span style='font-style:normal'>may increase the effect of
medicines used to lower the blood pressure. Be sure to tell your doctor if you
take a medicine to keep your blood pressure under control.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Receiving
</span></em><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>with some medicines may mean the doctor will need to
change your dose of </span></em>Abilify Maintena <em><span style='font-style:
normal'>or the other medicines. It is especially important to mention the
following to your doctor:</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        medicines to correct
heart rhythm (such as quinidine, amiodarone, flecainide)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        antidepressants or
herbal remedy used to treat depression and anxiety</span></em><span
class=berschrift4Zchn><i><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> </span></i></span><span class=berschrift4Zchn><span lang=EN-GB
style='font-family:"Times New Roman",serif;color:black;font-weight:normal'>(</span></span><em><span
lang=EN-GB style='color:black;font-style:normal'>such as fluoxetine,
paroxetine, St. John's Wort)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        antifungal medicines
(such as ketoconazole, itraconazole)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        certain medicines to
treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors
e.g. indinavir, ritonavir)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        anticonvulsants used
to treat epilepsy (such as </span></em><span class=BMSHeading3Char><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>carbamazepine,
phenytoin,</span></span><span class=BMSHeading3Char><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'> </span></i></span><em><span
lang=EN-GB style='color:black;font-style:normal'>phenobarbital)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        certain antibiotics
used to treat tuberculosis (rifabutin, rifampicin)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        medicines that are
known to prolong QT prolongation.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>These medicines
may increase the risk of side effects or reduce the effect of <span
style='color:black'>Abilify Maintena</span>; if you get any unusual symptom
taking any of these medicines together with <span style='color:black'>Abilify
Maintena</span>, you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt;color:black'>Medicines
that increase the level of serotonin </span><span class=BMSHeading3Char><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>are typically used in conditions including depression,
generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social
phobia as well as migraine and pain</span></span><span lang=EN-GB
style='font-size:11.0pt;color:black'>:</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt'>triptans, tramadol and tryptophan used for
conditions including depression, generalised anxiety disorder, obsessive
compulsive disorder (OCD) and social phobia as well as migraine and pain</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>SSRI s (such as paroxetine and
fluoxetine) used for depression, OCD, panic and anxiety</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>other anti-depressants (such as
venlafaxine and tryptophan) used in major depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>tricyclics (such as
clomipramine and amitriptyline) used for depressive illness</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>St Johns Wort (<i>Hypericum
perforatum</i>) used as a herbal remedy for mild depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>painkillers (such as tramadol
and pethidine) used for pain relief</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>triptans (such as sumatriptan
and zolmitripitan) used for treating migraine.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>These medicines
may increase the risk of side effects; if you get any unusual symptom taking
any of these medicines together with <span style='color:black'>Abilify Maintena</span>,
you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>with alcohol</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Alcohol
should be avoided.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Pregnancy,
breast-feeding and fertility</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you are pregnant or breast-feeding, think you may be pregnant or are planning
to have a baby, ask your doctor for advice before receiving this medicine.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>You
should not be given </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena <em><span style='font-style:normal'>if you are pregnant unless you
have</span></em></span></b><em><span lang=EN-GB style='color:black;font-style:
normal'> discussed this with your doctor. </span></em><span lang=EN-GB
style='color:black'>Be sure to tell your doctor immediately if you are
pregnant, think you may be pregnant, or if you are planning to become pregnant.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
following symptoms may occur in new-born babies, of mothers that have received </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>in the last trimester (last three months of their pregnancy):</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>shaking,
muscle stiffness and/or weakness, sleepiness, agitation, breathing problems,
and difficulty in feeding.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
your baby develops any of these symptoms you need to contact your doctor.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you are receiving </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena<em><span style='font-style:normal'>, your doctor will discuss with you
whether you should breast-feed considering the benefit to you of your therapy
and the benefit to your baby of breast-feeding. You should not do both. Talk to
your doctor about the best way to feed your baby if you are receiving </span></em>Abilify
Maintena<em><span style='font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Driving
and using machines</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness and vision problems may occur
during treatment with this medicine (see section&nbsp;4). This should be
considered in cases where full alertness is required, e.g., when driving a car
or handling machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Abilify Maintena contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Abilify Maintena contains less than 1&nbsp;mmol
sodium (23&nbsp;mg) per dose. This means that the medicine is essentially
sodium-free.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>3.       How </span></b></em><b><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is given</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Abilify
Maintena comes as a powder which your doctor or nurse will make into a
suspension.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Your doctor
will decide on the dose of Abilify Maintena that is right for you. The
recommended starting dose is 400&nbsp;mg unless your doctor decided to give you
a lower starting or follow up dose (300&nbsp;mg, 200&nbsp;mg or 160&nbsp;mg).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>There are two ways to start
Abilify Maintena, your doctor will decide which way is right for you.</p>

<p class=MsoNormal style='text-autospace:none'><em><span style='color:black;
font-style:normal'>        </span></em>If you are given one injection of
Abilify Maintena on your first day the <span lang=EN-GB>treatment with     aripiprazole
by mouth is continued for 14&nbsp;days after the first injection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span style='color:black;font-style:normal'>        </span></em>If
you are given two injections of Abilify Maintena on your first day, you will
also take one tablet of aripiprazole by mouth at this visit.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After that,
treatment is given with injections of&nbsp;Abilify Maintena unless your doctor
tells you otherwise.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Your doctor
will give it to you as a single injection into the gluteal or deltoid muscle
(buttock or shoulder) every month. You may feel a little pain during the
injection. Your doctor will alternate the injections between your right and
left side. The injections will not be given intravenously.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you are given more </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena <em><span style='font-style:normal'>than you should</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>This
medicine will be given to you under medical supervision; it is therefore
unlikely that you will be given too much. If you see more than one doctor, be
sure to tell them that you are receiving </span></em><span lang=EN-GB
style='color:black'>Abilify Maintena<em><span style='font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Patients
who have been given too much aripiprazole have experienced the following
symptoms:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        rapid heartbeat,
agitation/aggressiveness, problems with speech.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        unusual movements
(especially of the face or tongue) and reduced level of consciousness.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Other
symptoms may include:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        acute confusion,
seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        muscle stiffness, and
drowsiness or sleepiness, slower breathing, choking, high or low blood
pressure, abnormal rhythms of the heart.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Contact
your doctor or hospital immediately if you experience any of the above.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you miss an injection of </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>It
is important not to miss your scheduled dose. You should be given an injection
every month but not before the 26&nbsp;days has passed from the last injection.
If you miss an injection, you should contact your doctor to arrange your next
injection as soon as you can.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you stop receiving </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not stop your treatment just because you feel better. It is important that you
carry on receiving </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena <em><span style='font-style:normal'>for as long as your doctor has
told you to.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you have any further questions on the use of this medicine, ask your doctor or
nurse.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.       Possible side effects</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Like
all medicines, this medicine can cause side effects, although not everybody
gets them.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tell
your doctor immediately if you have any of the following serious side effects:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        a combination of any
of these symptoms: excessive sleepiness, dizziness, confusion, disorientation,
difficulty talking, difficulty walking, muscle stiffness or shaking, fever,
weakness, irritability, aggression, anxiety, increase in blood pressure, or seizures
that can lead to unconsciousness.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        unusual movement
mainly of the face or tongue, since your doctor may want to lower your dose.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        if you have symptoms
such as swelling, pain, and redness in the leg, because this may mean you have
a blood clot, which may travel through blood vessels to the lungs causing chest
pain and difficulty in breathing. If you notice any of these symptoms seek
medical advice immediately.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        a combination of
fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness
since this may be a sign of a condition called neuroleptic malignant syndrome
(NMS).</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        thirstiness more than
usual, need to urinate more than usual, feel very hungry, feel weak or tired,
feel sick, feel confused or your breath smells fruity, since this may be a sign
of diabetes.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
side effects listed below may also occur after receiving Abilify Maintena.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black'>Common side effects (may affect up to 1 in 10&nbsp;people):</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        weight
gain</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        diabetes
mellitus</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        weight
loss</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>feeling restless</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>feeling anxious</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>unable to keep still, difficulty sitting still</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>difficulty sleeping (insomnia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>jerky resistance to passive movement as muscles
tense and relax, abnormally increased muscle tone, slow body movement</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>akathisia (an uncomfortable feeling of inner
restlessness and a compelling need to move constantly)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>shaking or trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>uncontrollable twitching, jerking or writhing
movements</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>changes in your level of alertness, drowsiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle stiffness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>inability to have or maintain an erection during
sexual intercourse</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>pain at the injection site, hardening of the
skin at the injection site</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>weakness, loss of strength or extreme tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>during blood tests your doctor may find higher
amounts of creatine phosphokinase in your blood (enzyme important for muscle
function)</span></p>

<p class=MsoNormal><em><span lang=EN-GB>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Uncommon side
effects (may affect up to 1 in 100&nbsp;people):</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>low level of a specific type of white blood
cells (neutropenia), low haemoglobin or red blood cell count, low level of
blood platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        decreased
or </span></em><span lang=EN-GB style='color:black'>increased blood levels of
the hormone prolactin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>high blood sugar</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>increased blood fats such as high cholesterol,
high triglycerides and also low level of cholesterol and low level of
triglycerides</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>increased levels of insulin, a hormone
regulating blood sugar levels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>decreased or increased appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>thoughts about suicide</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>mental disorder characterized by defective or
lost contact with reality</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>hallucination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>delusion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>increased sexual interest</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>panic reaction</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>affect lability</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>state of indifference with lack of emotion,
feelings of emotional and mental discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>sleep disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>grinding of teeth or clenching of the jaw</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>reduced sexual interest (libido is decreased)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>altered mood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle movements that you cannot control such as
grimacing, lip-smacking and tongue movements. They usually affect the face and
mouth first but can affect other parts of the body. These could be signs of a
condition called tardive dyskinesia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>parkinsonism - medical condition with many
various symptoms which include decreased or slow movements, slowness of
thought, jerks when bending the limbs (cogwheel rigidity), shuffling, hurried
steps, shaking, little or no facial expression, muscle stiffness, drooling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>movement problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>extreme restlesness and restless legs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>distortion of the senses of taste and smell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>fixation of the eyeballs in one position</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>blurred vision</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>eye pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>double vision</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
style='color:black;font-style:normal'>        eye sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>abnormal heartbeat, slow or fast heart rate,
abnormal electrical conduction of the heart, abnormal reading (ECG) of the
heart</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>high blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dizziness when getting up from a lying or
sitting position due to a drop in blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>hiccups</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>gastroesophageal reflux disease. Excess amount
of gastric juice flowing back (refluxes) into the esophagus (gullet or the tube
that goes from mouth to stomach through which food passes), causing heartburn
and possibly damaging the esophagus</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>heartburn</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>feeling sick</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>stomach ache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>stomach discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>frequent bowel movement</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>drooling, more saliva in mouth than normal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>abnormal hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>acne, skin condition of the face where the nose
and cheeks are unusually red, eczema,<em><span style='font-style:normal'> </span></em>skin
hardening</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle rigidity, muscle spasms, muscle
twitching, muscle tightness, mucle pain (myalgia), pain in extremity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>joint pain ( arthralgia), back pain, decreased range
of motion of joints, stiff neck, limited opening of mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>kidney stones, sugar (glucose) in urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>spontaneous flow of milk from the breasts
(galactorrhoea)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>enlargement of breast in men, breast tenderness,
vaginal dryness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>loss of strength</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>gait disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>chest discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>injection site reactions such as redness,
swelling discomfort and injection site itching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>thirst</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>sluggishness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>liver function tests may show abnormal results</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>during tests your doctor may find</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of liver
enzymes</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of alanine
aminotransferase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of
gamma-glutamyl transferase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of bilirubin
in your blood</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of aspartate
aminotransferase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher or lower amounts of
blood glucose</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of
glycosylated haemoglobin</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        lower amounts of cholesterol
in your blood</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        lower amounts of triglycerides
in your blood</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        a higher waist
circumference</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>The following side
effects have been reported since the marketing of oral aripiprazole but the
frequency for them to occur is not known (frequency cannot be estimated from
the available data):</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        low levels of white
blood cells</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        allergic reaction
(e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        unusual heartbeat,
sudden unexplained death, heart attack</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        diabetic ketoacidosis
(ketones in the blood and urine) or coma</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        loss of appetite
(anorexia), </span></em><span lang=EN-GB style='color:black'>difficulty in
swallowing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        low sodium level in
the blood</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        suicide attempt and
suicide</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>inability to resist the impulse, drive or temptation to perform an
action that could be harmful to you or others, which may include:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        strong impulse to gamble excessively despite
serious personal or family consequences</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        altered or increased sexual interest and
behaviour of significant concern to you or to others, for example, an increased
sexual drive</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        uncontrollable excessive shopping</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        binge eating (eating large amounts of food in a
short time period) or compulsive eating (eating more food than normal and more
than is needed to satisfy your hunger)</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        a tendency to wander away</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>Tell your doctor if you experience any of these behaviours; he/she
will discuss ways of managing or reducing the symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        nervousness</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>aggression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        neuroleptic malignant
syndrome ( a syndrome with symptoms such as fever, muscle stiffness, faster
breathing, sweating, reduced consciousness and sudden changes in blood pressure
and heart rate)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        seizure (fits)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>serotonin syndrome (a reaction which may cause feelings of great
happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever,
sweating or rigid muscles)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>speech disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>heart problems including torsades de pointes,
stopping of the heart, irregularities in heart rhythm that may be due to
abnormal nerve impulses in the heart, abnormal readings during heart
examination (ECG) QT prolongation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        fainting</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>symptoms related to blood clots in the veins especially
in the legs (symptoms include swelling, pain and redness in the leg), which may
travel through blood vessels to the lungs causing chest pain and difficulty in
breathing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        spasm of the muscles
around the voice box</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        accidental inhalation
of food with risk of pneumonia (lung infection)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        inflammation of the
pancreas</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        difficulty swallowing</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        liver failure</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        jaundice (yellowing
of the skin and white part of eyes)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        inflammation of the
liver</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        rash</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><em><span
style='color:black;font-style:normal'>skin </span></em><em><span lang=EN-GB
style='color:black;font-style:normal'>sensitivity to light</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        excessive sweating</span></em></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>serious allergic reactions such as Drug Reaction with Eosinophilia and
Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a
rash on the face and then with an extended rash, high temperature, enlarged
lymph nodes, increased levels of liver enzymes seen in blood tests and an
increase in a type of white blood cell (eosinophilia). </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle weakness, tenderness or pain and
particularly, if at the same time, you feel unwell, have a high temperature or
have dark urine. They may be caused by an abnormal muscle breakdown which can
be life threatening and lead to kidney problems (a condition called
rhabdomyolysis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        difficulty in passing
urine</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        involuntary loss of
urine (incontinence)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        drug withdrawal symptoms
in new-born infant</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        prolonged and/or
painful erection</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        difficulty
controlling core body temperature or overheating</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        chest pain</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        swelling of hands,
ankles or feet</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>during tests your doctor may find</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts alkaline
phosphatase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        fluctuating results during
tests to measure glucose in your blood</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
style='color:black;font-style:normal'>Reporting of side effects</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or nurse. This includes any possible side effects not listed in this
leaflet. You can also report side effects directly via <span style='background:
silver'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span
style='background:silver'>Appendix V</span></u></a>. By reporting side effects,
you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='text-align:justify'><em><span lang=EN-GB
style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>5.       How to store </span></b></em><b><span
lang=EN-GB style='color:black'>Abilify Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Keep
this medicine out of the sight and reach of children.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not use this medicine after the expiry date which is stated on the carton and
the vial. The expiry date refers to the last day of that month.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not freeze.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
reconstituted suspension should be used immediately but may be stored below
25°C for up to 4&nbsp;hours in the vial. Do not store the reconstituted
suspension in the syringe.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.       Contents of the pack
and other information</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>What
</span></b></em><b><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>contains</span></em></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        The active substance
is aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Each vial contains 300&nbsp;mg
aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>After reconstitution each ml of
suspension contains 200&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Each vial contains 400&nbsp;mg
aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>After reconstitution each ml of
suspension contains 200&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        The other ingredients
are</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Powder</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Carmellose sodium, mannitol, sodium
dihydrogen phosphate monohydrate, sodium hydroxide</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Solvent</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Water for injections</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>What
</span></b></em><b><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>looks like and contents of the pack</span></em></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>is a powder and solvent for prolonged-release suspension
for injection.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>comes as a white to off-white powder in a clear glass
vial. Your doctor or nurse will make it into a suspension that will be given as
an injection using the vial of solvent for </span></em>Abilify Maintena <em><span
style='font-style:normal'>that comes as a clear solution in a clear glass vial.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Single pack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
single pack containing one vial of powder, 2&nbsp;ml vial of solvent, one
3&nbsp;ml luer lock syringe with pre-attached 38&nbsp;mm (1.5&nbsp;inch)
21&nbsp;gauge, hypodermic safety needle with needle protection device, one
3&nbsp;ml disposable syringe with luer lock tip, one vial adapter and three
hypodermic safety needles: one 25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge, one
38&nbsp;mm (1.5&nbsp;inch) 22&nbsp;gauge and one 51&nbsp;mm (2&nbsp;inch)
21&nbsp;gauge.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Multipack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Bundle
pack of 3 single packs.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Not
all pack sizes may be marketed.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
style='color:black;font-style:normal'>Marketing Authorisation Holder</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Manufacturer</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>H.
Lundbeck A/S</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Ottiliavej
9, 2500 Valby</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Denmark</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>For
any information about this medicine, please contact the local representative of
the Marketing Authorisation Holder:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>België/Belgique/Belgien</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  S.A./N.V.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tél/Tel:&nbsp;+32
  2 535 79 79</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Lietuva</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Export A/S Representative Office</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+359
  2 962 4696</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Luxembourg/Luxemburg</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  S.A.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tél:&nbsp;+32
  2 535 79 79</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:38.1pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:38.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#268;eská republika</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  &#268;eská republika s.r.o.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+420
  225 275 600</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:38.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Magyarország</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Hungaria Kft.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+36
  1 4369980</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:46.1pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:46.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Danmark</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:46.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Malta</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Deutschland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma GmbH</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+49
  69 1700860</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Nederland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  B.V.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+31
  20 697 1901</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Eesti</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Norge</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Hellas S.A.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&#932;&#951;&#955;:&nbsp;+30
  210 610 5036</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Österreich</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Austria GmbH</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+43
  1 266 91 08</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>España</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceutical S.A.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+34
  93 208 10 20</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Polska</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Poland Sp. z o. o.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel.:&nbsp;+48
  22 626 93 00</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>France</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceutical France SAS</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tél:&nbsp;+33
  (0)1 47 08 00 00</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Portugal</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Portugal Lda</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+351
  21 00 45 900</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Hrvatska</span></b></em></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Lundbeck Croatia
  d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel.:&nbsp;+385 1 644
  82 63</span></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>România</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  </span></em><em><span lang=EN-GB style='color:black;font-style:normal'>Export
  A/S</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Reprezentanta
  din </span></em><em><span lang=EN-GB style='color:black;font-style:normal'>Romania</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+40
  21319 88 26</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
  style='color:black;font-style:normal'>Ireland</span></b></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Lundbeck (Ireland) Limited</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Tel:&nbsp;+353 1 468 9800</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
  style='color:black;font-style:normal'>Slovenija</span></b></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Lundbeck Pharma d.o.o.</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Tel.:&nbsp;+386 2 229 4500</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
  style='color:black;font-style:normal'>Ísland</span></b></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sími: +354
  535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
  style='color:black;font-style:normal'>Slovenská republika</span></b></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Lundbeck Slovensko s.r.o.</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Tel:&nbsp;+421 2 5341 42 18</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Italia</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceutical Italy S.r.l</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+39
  02 00 63 27 10</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Suomi/Finland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Hellas A.E</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&#932;&#951;&#955;.:&nbsp;+357
  22490305</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Sverige</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Latvija</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>United Kingdom</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceuticals (UK) Ltd.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+44
  203 747 5300</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr height=0>
  <td width=351 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=351 style='border:none'></td>
  <td width=3 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in <span
style='color:black'>{MM/YYYY}.</span></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span></em><span lang=EN-GB><a href="http://www.ema.europa.eu/"><u>http://www.ema.europa.eu</u></a><em><span
style='color:black;font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<em><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></em>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>---------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal align=center style='text-align:center'><em><span lang=EN-GB
style='color:black;font-style:normal'>The following information is intended for
healthcare professionals only:</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>INSTRUCTIONS FOR HEALTH CARE
PROFESSIONALS</span></b></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Any
unused medicinal product or waste material should be disposed of in accordance
with local requirements.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></b></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>aripiprazole</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;1:
Preparation prior to reconstitution of the powder</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lay
out and confirm that components listed below are provided:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Abilify Maintena
package leaflet and instructions for healthcare professionals.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Vial of powder.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        2&nbsp;ml vial of
solvent.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>          Important:</span></b><span lang=EN-GB> the
solvent vial contains an overfill.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One 3&nbsp;ml luer
lock syringe with pre-attached 38&nbsp;mm (1.5&nbsp;inch) 21&nbsp;gauge
hypodermic safety needle with needle protection device.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One 3&nbsp;ml
disposable syringe with luer lock tip.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One vial adapter.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-        One 25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge hypodermic
safety needle<em><span style='font-style:normal'> with needle protection device.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One 38&nbsp;mm
(1.5&nbsp;inch) 22&nbsp;gauge hypodermic safety needle with needle protection
device.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One 51&nbsp;mm
(2&nbsp;inch) 21&nbsp;gauge hypodermic safety needle with needle protection
device.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Syringe and needle
instructions.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;2:
Reconstitution of the powder</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>a)       Remove the solvent
and powder vial caps and wipe the tops with a sterile alcohol swab.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>b)      Using the syringe with
pre-attached needle, withdraw the pre-determined solvent volume from the vial
of the solvent into the syringe.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>300&nbsp;mg vial:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>Add 1.5&nbsp;ml solvent to reconstitute the powder.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>400&nbsp;mg vial:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>Add 1.9&nbsp;ml solvent to reconstitute the powder.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>A small amount of residual solvent will
remain in the vial following withdrawal. Any excess should be discarded.</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><em><span style='font-style:normal'><img border=0 width=624 height=178
src="Abilify%20Maintena_clean_files/image002.png"></span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>c)  Slowly inject the solvent
into the vial containing the powder.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>d)      Withdraw air to
equalise the pressure in the vial by pulling back slightly on the plunger.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><a
name="_Hlk498354571"><span lang=EN-GB style='color:black'><img border=0
width=53 height=137 id="Bild 3"
src="Abilify%20Maintena_clean_files/image003.png" alt="Pic 2"></span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>e)       Subsequently, remove
the needle from the vial.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>          Engage the needle
safety device by using the one-handed technique.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Gently press the sheath against a flat
surface until the needle is firmly engaged in the needle protection sheath.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>          Visually confirm
that the needle is fully engaged into the needle protection sheath, and
discard.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><em><span style='font-style:normal'><img border=0 width=624 height=130
src="Abilify%20Maintena_clean_files/image004.png"></span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>f)       <u>Shake the vial
vigorously for 30&nbsp;seconds until the suspension appears uniform.</u></span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><a
name="_Hlk498354543"><span lang=EN-GB style='color:black'><img border=0
width=135 height=132 id="Bild 6"
src="Abilify%20Maintena_clean_files/image005.png" alt="Pic 4"></span></a></p>

<p class=MsoNormal align=center style='text-align:center'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>g)       Visually inspect the
reconstituted suspension for particulate matter and discolouration prior to
administration. The reconstituted medicine is a white to off-white, fluid
suspension. Do not use if reconstituted suspension contains particulate matter
or any discolouration.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>h)      If the injection is
not performed immediately after reconstitution, keep the vial below 25&nbsp;°C
for up to 4&nbsp;hours and shake it vigorously for at least 60&nbsp;seconds to
re-suspend prior to injection.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>i)       Do not store the
reconstituted suspension in the syringe.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;3:
Preparation prior to injection</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>a)       Remove the cover, but
not the adapter from the package.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>b)      Using the vial adapter
package to handle the vial adapter, attach the pre-packaged luer lock syringe
to the vial adapter.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><a
name="_Hlk498354528"><span lang=EN-GB><img border=0 width=89 height=133
id="Grafik 11" src="Abilify%20Maintena_clean_files/image006.png"></span></a></p>

<p class=MsoNormal style='margin-left:21.0pt;text-indent:-21.0pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>c)       Use the luer lock
syringe to remove the vial adapter from the package and discard the vial
adapter package. <u>Do not touch the spike tip of the adapter at any time.</u></span></em></p>

<p class=MsoNormal style='margin-left:21.0pt;text-indent:-21.0pt'><em><u><span
lang=EN-GB style='color:black;font-style:normal'><span style='text-decoration:
 none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal align=center style='text-align:center'><a
name="_Hlk498354519"><span lang=EN-GB><img border=0 width=70 height=133
id="Grafik 19" src="Abilify%20Maintena_clean_files/image007.png"></span></a></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>d)      Determine the
recommended volume for injection.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=288
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=288 colspan=2 valign=top style='width:215.65pt;border:solid windowtext 1.0pt;
  border-left:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>Abilify Maintena 300&nbsp;mg
  Vial</span></b></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Dose</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Volume to Inject</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>---</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>---</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>300&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>1.5&nbsp;ml</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>200&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>1.0&nbsp;ml</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>160&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>0.8&nbsp;ml</span></em></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=288
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=288 colspan=2 valign=top style='width:215.65pt;border:solid windowtext 1.0pt;
  border-left:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><b><span
  lang=EN-GB style='color:black;font-style:normal'>Abilify Maintena 400&nbsp;mg
  Vial</span></b></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Dose</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>Volume to Inject</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>400&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>2.0&nbsp;ml</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>300&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>1.5&nbsp;ml</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>200&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>1.0&nbsp;ml</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:90.05pt;border-top:none;border-left:
  double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>160&nbsp;mg</span></em></p>
  </td>
  <td width=167 valign=top style='width:125.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><em><span
  lang=EN-GB style='color:black;font-style:normal'>0.8&nbsp;ml</span></em></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>e)       Wipe the top of the
vial of the reconstituted suspension with a sterile alcohol swab.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>f)       Place and hold the
vial of the reconstituted suspension on a hard surface. Attach the adapter-syringe
assembly to the vial by holding the outside of the adapter and pushing the
adapters spike firmly through the rubber stopper, until the adapter snaps in
place.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>g)       Slowly withdraw the
recommended volume from the vial into the luer lock syringe to allow for
injection.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>          <u>A
small amount of excess product will remain in the vial.</u></span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><a
name="_Hlk498354506"><span lang=EN-GB><img border=0 width=58 height=139
id="Grafik 16" src="Abilify%20Maintena_clean_files/image008.png"></span></a></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;4:
Injection procedure</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>a)       Detach the luer lock
syringe containing the recommended volume of reconstituted Abilify Maintena
suspension from the vial.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>b)      Select one of the
following hypodermic safety needles depending on the injection site and patients
weight and attach the needle to the luer lock syringe containing the suspension
for injection. Ensure the needle is firmly seated on the needle protection
device with a push and clockwise twist and then pull the needle cap straight
away from the needle.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:33.75pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Body type</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Injection site</span></b></p>
  </td>
  <td width=265 valign=top style='width:198.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Needle size</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Non-obese</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Deltoid</span></b></p>
  </td>
  <td width=265 valign=top style='width:198.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Gluteal</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=265 valign=top style='width:198.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>38&nbsp;mm (1.5&nbsp;inch)
  22&nbsp;gauge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Obese</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Deltoid</span></b></p>
  </td>
  <td width=265 valign=top style='width:198.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>38&nbsp;mm (1.5&nbsp;inch)
  22&nbsp;gauge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Gluteal</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=265 valign=top style='width:198.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>51&nbsp;mm (2&nbsp;inch) 21&nbsp;gauge</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>c)       Slowly inject the recommended
volume as a single intramuscular injection into the gluteal or deltoid muscle.
Do not massage the injection site. Care must be taken to avoid inadvertent
injection into the blood vessel. Do not inject into an area with signs of
inflammation, skin damage, lumps and/or bruises.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>For deep intramuscular gluteal or deltoid injection only.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='line-height:12.0pt'><img border=0 width=624
height=215 src="Abilify%20Maintena_clean_files/image009.png"></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB
style='color:black'>Remember to rotate sites of injections between the two
gluteal or deltoid muscles. </span></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB
style='color:black'>If initiating with the two injection start, inject into two
different sites in two different muscles. </span><span lang=EN-GB>DO NOT inject
both injections concomitantly into the same deltoid or gluteal muscle.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB>For known CYP2D6
poor metabolisers administer in either<s> </s>two separate deltoid muscles or
one deltoid and one gluteal muscle.</span><em><span lang=EN-GB
style='color:black;font-style:normal'> </span></em><span lang=EN-GB>DO NOT
inject into two gluteal muscles.</span></p>

<p class=MsoNormal style='margin-left:31.5pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Look for signs or symptoms of inadvertent
intravenous administration.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;5:
Procedures after injection</span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Engage the
needle safety device as described in Step&nbsp;2 e). Dispose of the vials, adapter,
needles, and syringe appropriately after injection. The powder and solvent
vials are for single-use only.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
text-autospace:none'><img border=0 width=624 height=130
src="Abilify%20Maintena_clean_files/image010.png"></p>

<em><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></em>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>Package leaflet: Information
for the user</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='color:black'>Abilify Maintena <em><span style='font-style:normal'>300&nbsp;mg
powder and solvent for prolonged-release suspension for injection in pre&#8209;filled
syringe</span></em></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='color:black'>Abilify Maintena <em><span style='font-style:normal'>400&nbsp;mg
powder and solvent for prolonged-release suspension for injection in pre&#8209;filled
syringe</span></em></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><em><span lang=EN-GB
style='color:black;font-style:normal'>aripiprazole</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Read
all of this leaflet carefully before you receive this medicine because it
contains important information for you.</span></b></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Keep this leaflet.
You may need to read it again.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        If you have any
further questions, ask your doctor or nurse.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        If you get any side
effects, talk to your doctor or nurse. This includes any possible side effects
not listed in this leaflet. See section&nbsp;4.</span></em></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>What is in this leaflet</span></b></em></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>1.       What </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is and what it is used for</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>2.       What you need to know
before you are given </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>3.       How </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is given</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>4.       Possible side effects</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>5.       How to store </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>6.       Contents of the pack
and other information</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>1.       What </span></b></em><b><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is and what it is used for</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>contains the active substance aripiprazole and
belongs to a group of medicines called antipsychotics. It is used to treat
schizophrenia - a disease with symptoms such as hearing, seeing or sensing
things which are not there, suspiciousness, mistaken beliefs, incoherent speech
and behaviour and emotional flatness. People with this condition may also feel
depressed, guilty, anxious or tense.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>is intended for adult patients with schizophrenia who
are sufficiently stabilised during treatment with oral aripiprazole.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>2.       What you need to know
before you are given </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Do
not use </span></b></em><b><span lang=EN-GB style='color:black'>Abilify Maintena</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'></span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>        if you are allergic to
aripiprazole or any of the other ingredients of this medicine (listed in
section&nbsp;6).</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Warnings
and precautions</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Talk
to your doctor or nurse before you are given </span></em><span lang=EN-GB
style='color:black'>Abilify Maintena<em><span style='font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Suicidal
thoughts and behaviours have been reported during aripiprazole treatment. Tell
your doctor immediately if you are having any thoughts or feelings about
hurting yourself.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Before
treatment with </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena<em><span style='font-style:normal'>, tell your doctor if you suffer
from</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        an acutely agitated
state or a severely psychotic state</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        heart problems or
have a history of stroke, especially if you know that you have other risks
factors for stroke</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        high blood sugar
(characterised by symptoms such as excessive thirst, passing of large amounts
of urine, increase in appetite and feeling weak) or family history of diabetes</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        fits (seizures) since
your doctor may want to monitor you more closely</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        involuntary,
irregular muscle movements, especially in the face</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>experience a combination of fever, sweating,
faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs
of neuroleptic malignant syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dementia (loss of memory and other mental
abilities) especially if you are elderly</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        cardiovascular
diseases (diseases of the heart and circulation), family history of
cardiovascular disease, stroke or &quot;mini&quot; stroke, abnormal blood
pressure</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        irregular heart beat
or if someone else in your family has a history of irregular heart beat
(including so called QT prolongation seen with ECG monitoring).</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        blood clots, or family
history of blood clots, as antipsychotics have been associated with formation
of blood clots</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>have any difficulty in swallowing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        past experience with
excessive gambling</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        severe liver
problems.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you notice you are gaining weight, develop unusual movements, experience
sleepiness that interferes with normal daily activities, any difficulty in
swallowing or have allergic symptoms, please talk to your doctor immediately.</span></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor if you or your
family/carer notices that you are developing urges or cravings to behave in
ways that are unusual for you and you cannot resist the impulse, drive or
temptation to carry out certain activities that could harm yourself or others.
These are called impulse control disorders and can include behaviours such as
addictive gambling, excessive eating or spending, an abnormally high sex drive
or preoccupation with an increase in sexual thoughts or feelings.</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Your doctor may need to adjust or stop
your dose.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:#212121'>Aripiprazole</span><span
style='color:#212121'> may cause sleepiness, fall in blood pressure when
standing up, dizziness and changes in your ability to move and balance, which
may lead to falls. Caution should be taken, particularly if you are an elderly
patient or have some debility.</span></p>

<p class=MsoNormal style='background:white'><span style='color:#212121'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not use this
medicine in children and adolescents under 18&nbsp;years of age. It is not known
if it is safe and effective in these patients.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Other
medicines and </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tell
your doctor if you are taking, have recently taken or might take any other
medicines.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Blood
pressure-lowering medicines:</span></em><span lang=EN-GB style='color:black'>
Abilify Maintena <em><span style='font-style:normal'>may increase the effect of
medicines used to lower the blood pressure. Be sure to tell your doctor if you
take a medicine to keep your blood pressure under control.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Receiving
</span></em><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>with some medicines may mean the doctor will need to
change your dose of </span></em>Abilify Maintena <em><span style='font-style:
normal'>or the other medicines. It is especially important to mention the
following to your doctor:</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        medicines to correct
heart rhythm (such as quinidine, amiodarone, flecainide)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        antidepressants or
herbal remedy used to treat depression and anxiety</span></em><span
class=berschrift4Zchn><i><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> </span></i></span><span class=berschrift4Zchn><span lang=EN-GB
style='font-family:"Times New Roman",serif;color:black;font-weight:normal'>(</span></span><em><span
lang=EN-GB style='color:black;font-style:normal'>such as fluoxetine,
paroxetine, St. John's Wort)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        antifungal medicines
(such as ketoconazole, itraconazole)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        certain medicines to
treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors e.g.
indinavir, ritonavir)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        anticonvulsants used
to treat epilepsy (such as </span></em><span class=BMSHeading3Char><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>carbamazepine,
phenytoin,</span></span><span class=BMSHeading3Char><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'> </span></i></span><em><span
lang=EN-GB style='color:black;font-style:normal'>phenobarbital)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        certain antibiotics
used to treat tuberculosis (rifabutin, rifampicin)</span></em></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        medicines
that are known to prolong QT prolongation.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>These medicines
may increase the risk of side effects or reduce the effect of <span
style='color:black'>Abilify Maintena</span>; if you get any unusual symptom
taking any of these medicines together with <span style='color:black'>Abilify
Maintena</span>, you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt;color:black'>Medicines
that increase the level of serotonin </span><span class=BMSHeading3Char><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-weight:normal'>are typically used in conditions including depression, generalised
anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well
as migraine and pain</span></span><span lang=EN-GB style='font-size:11.0pt;
color:black'>:</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt'>triptans, tramadol and tryptophan used for
conditions including depression, generalised anxiety disorder, obsessive
compulsive disorder (OCD) and social phobia as well as migraine and pain</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>SSRI s (such as paroxetine and
fluoxetine) used for depression, OCD, panic and anxiety</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>other anti-depressants (such as
venlafaxine and tryptophan) used in major depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>tricyclics (such as clomipramine
and amitriptyline) used for depressive illness</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>St Johns Wort (<i>Hypericum
perforatum</i>) used as a herbal remedy for mild depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>painkillers (such as tramadol
and pethidine) used for pain relief</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='font-size:11.0pt;color:black'>triptans (such as sumatriptan
and zolmitripitan) used for treating migraine.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>These medicines
may increase the risk of side effects; if you get any unusual symptom taking
any of these medicines together with <span style='color:black'>Abilify Maintena</span>,
you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>with alcohol</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Alcohol
should be avoided.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Pregnancy,
breast-feeding and fertility</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you are pregnant or breast-feeding, think you may be pregnant or are planning
to have a baby, ask your doctor for advice before receiving this medicine.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>You
should not be given </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena <em><span style='font-style:normal'>if you are pregnant unless you
have</span></em></span></b><em><span lang=EN-GB style='color:black;font-style:
normal'> discussed this with your doctor. </span></em><span lang=EN-GB
style='color:black'>Be sure to tell your doctor immediately if you are
pregnant, think you may be pregnant, or if you are planning to become pregnant.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
following symptoms may occur in new-born babies, of mothers that have received </span></em><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>in the last trimester (last three months of their pregnancy):</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>shaking,
muscle stiffness and/or weakness, sleepiness, agitation, breathing problems,
and difficulty in feeding.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
your baby develops any of these symptoms you need to contact your doctor.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you are receiving </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena<em><span style='font-style:normal'>, your doctor will discuss with you
whether you should breast-feed considering the benefit to you of your therapy
and the benefit to your baby of breast-feeding. You should not do both. Talk to
your doctor about the best way to feed your baby if you are receiving </span></em>Abilify
Maintena<em><span style='font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Driving
and using machines</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness and vision problems may occur
during treatment with this medicine (see section&nbsp;4). This should be
considered in cases where full alertness is required, e.g., when driving a car
or handling machines.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>Abilify Maintena contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Abilify Maintena contains less than 1&nbsp;mmol
sodium (23&nbsp;mg) per dose. This means that the medicine is essentially
sodium-free.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>3.       How </span></b></em><b><span
lang=EN-GB style='color:black'>Abilify Maintena <em><span style='font-style:
normal'>is given</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Abilify
Maintena comes as a pre&#8209;filled&nbsp;syringe.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Your doctor
will decide on the dose of Abilify Maintena that is right for you. The
recommended starting dose is 400&nbsp;mg unless your doctor decided to give you
a lower starting or follow up dose (300&nbsp;mg, 200&nbsp;mg or 160&nbsp;mg).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>There are two ways to start
Abilify Maintena, your doctor will decide which way is right for you.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span style='color:black;font-style:normal'>        </span></em><em><span
style='color:black;font-style:normal'>If you are given one injection of Abilify
Maintena on your first day the </span></em><em><span lang=EN-GB
style='color:black;font-style:normal'>treatment with aripiprazole by </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>mouth</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'> is continued for 14&nbsp;days
after the first injection.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>If you are given two injections of Abilify Maintena on your first
day, you will also take one tablet of aripiprazole by mouth at this visit.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After that,
treatment is given with injections of&nbsp;Abilify Maintena unless your doctor
tells you otherwise.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Your doctor
will give it to you as a single injection into the gluteal or deltoid muscle
(buttock or shoulder) every month. You may feel a little pain during the
injection. Your doctor will alternate the injections between your right and
left side. The injections will not be given intravenously.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you are given more </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena <em><span style='font-style:normal'>than you should</span></em></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>This
medicine will be given to you under medical supervision; it is therefore
unlikely that you will be given too much. If you see more than one doctor, be
sure to tell them that you are receiving </span></em><span lang=EN-GB
style='color:black'>Abilify Maintena<em><span style='font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Patients
who have been given too much aripiprazole have experienced the following
symptoms:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        rapid heartbeat,
agitation/aggressiveness, problems with speech.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        unusual movements
(especially of the face or tongue) and reduced level of consciousness.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Other
symptoms may include:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        acute confusion,
seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        muscle stiffness, and
drowsiness or sleepiness, slower breathing, choking, high or low blood
pressure, abnormal rhythms of the heart.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Contact
your doctor or hospital immediately if you experience any of the above.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you miss an injection of </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>It
is important not to miss your scheduled dose. You should be given an injection
every month but not before the 26&nbsp;days has passed from the last injection.
If you miss an injection, you should contact your doctor to arrange your next
injection as soon as you can.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you stop receiving </span></b></em><b><span lang=EN-GB style='color:black'>Abilify
Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not stop your treatment just because you feel better. It is important that you
carry on receiving </span></em><span lang=EN-GB style='color:black'>Abilify
Maintena <em><span style='font-style:normal'>for as long as your doctor has
told you to.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you have any further questions on the use of this medicine, ask your doctor or
nurse.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>4.       Possible side effects</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Like
all medicines, this medicine can cause side effects, although not everybody
gets them.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tell
your doctor immediately if you have any of the following serious side effects:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        a combination of any
of these symptoms: excessive sleepiness, dizziness, confusion, disorientation,
difficulty talking, difficulty walking, muscle stiffness or shaking, fever,
weakness, irritability, aggression, anxiety, increase in blood pressure, or
seizures that can lead to unconsciousness.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        unusual movement
mainly of the face or tongue, since your doctor may want to lower your dose.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        if you have symptoms
such as swelling, pain, and redness in the leg, because this may mean you have
a blood clot, which may travel through blood vessels to the lungs causing chest
pain and difficulty in breathing. If you notice any of these symptoms seek
medical advice immediately.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        a combination of
fever, faster breathing, sweating, muscle stiffness and drowsiness or
sleepiness since this may be a sign of a condition called neuroleptic malignant
syndrome (NMS).</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        thirstiness more than
usual, need to urinate more than usual, feel very hungry, feel weak or tired,
feel sick, feel confused or your breath smells fruity, since this may be a sign
of diabetes.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
side effects listed below may also occur after receiving Abilify Maintena.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><em><span
lang=EN-GB style='color:black'>Common side effects (may affect up to 1 in
10&nbsp;people):</span></em></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        weight
gain</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        diabetes
mellitus</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        weight
loss</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>feeling restless</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>feeling anxious</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>unable to keep still, difficulty sitting still</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>difficulty sleeping (insomnia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>jerky resistance to passive movement as muscles
tense and relax, abnormally increased muscle tone, slow body movement</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>akathisia (an uncomfortable feeling of inner
restlessness and a compelling need to move constantly)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>shaking or trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>uncontrollable twitching, jerking or writhing
movements</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>changes in your level of alertness, drowsiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle stiffness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>inability to have or maintain an erection during
sexual intercourse</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>pain at the injection site, hardening of the
skin at the injection site</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>weakness, loss of strength or extreme tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>during blood tests your doctor may find higher
amounts of creatine phosphokinase in your blood (enzyme important for muscle
function)</span></p>

<p class=MsoNormal><em><span lang=EN-GB>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Uncommon side
effects (may affect up to 1 in 100&nbsp;people):</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>low level of a specific type of white blood
cells (neutropenia), low haemoglobin or red blood cell count, low level of
blood platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        decreased
or </span></em><span lang=EN-GB style='color:black'>increased blood levels of
the hormone prolactin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>high blood sugar</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>increased blood fats such as high cholesterol,
high triglycerides and also low level of cholesterol and low level of
triglycerides</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>increased levels of insulin, a hormone
regulating blood sugar levels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>decreased or increased appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>thoughts about suicide</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>mental disorder characterized by defective or
lost contact with reality</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>hallucination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>delusion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>increased sexual interest</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>panic reaction</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>affect lability</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>state of indifference with lack of emotion,
feelings of emotional and mental discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>sleep disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>grinding of teeth or clenching of the jaw</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>reduced sexual interest (libido is decreased)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>altered mood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle movements that you cannot control such as
grimacing, lip-smacking and tongue movements. They usually affect the face and
mouth first but can affect other parts of the body. These could be signs of a
condition called tardive dyskinesia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>parkinsonism - medical condition with many
various symptoms which include decreased or slow movements, slowness of
thought, jerks when bending the limbs (cogwheel rigidity), shuffling, hurried
steps, shaking, little or no facial expression, muscle stiffness, drooling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>movement problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>extreme restlesness and restless legs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>distortion of the senses of taste and smell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>fixation of the eyeballs in one position</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>blurred vision</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>eye pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>double vision</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
style='color:black;font-style:normal'>        eye sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>abnormal heartbeat, slow or fast heart rate,
abnormal electrical conduction of the heart, abnormal reading (ECG) of the
heart</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>high blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>dizziness when getting up from a lying or
sitting position due to a drop in blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>hiccups</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>gastroesophageal reflux disease. Excess amount
of gastric juice flowing back (refluxes) into the esophagus (gullet or the tube
that goes from mouth to stomach through which food passes), causing heartburn
and possibly damaging the esophagus</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>heartburn</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>feeling sick</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>stomach ache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>stomach discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>frequent bowel movement</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>drooling, more saliva in mouth than normal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>abnormal hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>acne, skin condition of the face where the nose
and cheeks are unusually red, eczema,<em><span style='font-style:normal'> </span></em>skin
hardening</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle rigidity, muscle spasms, muscle
twitching, muscle tightness, mucle pain (myalgia), pain in extremity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>joint pain ( arthralgia), back pain, decreased
range of motion of joints, stiff neck, limited opening of mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>kidney stones, sugar (glucose) in urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>spontaneous flow of milk from the breasts
(galactorrhoea)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>enlargement of breast in men, breast tenderness,
vaginal dryness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>loss of strength</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>gait disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>chest discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>injection site reactions such as redness,
swelling discomfort and injection site itching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>thirst</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>sluggishness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>liver function tests may show abnormal results</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>during tests your doctor may find</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of liver
enzymes</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of alanine
aminotransferase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of
gamma-glutamyl transferase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of bilirubin
in your blood</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of aspartate
aminotransferase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher or lower amounts of
blood glucose</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts of
glycosylated haemoglobin</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        lower amounts of
cholesterol in your blood</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        lower amounts of triglycerides
in your blood</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        a higher waist
circumference</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>The following side
effects have been reported since the marketing of oral aripiprazole but the
frequency for them to occur is not known (frequency cannot be estimated from
the available data):</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        low levels of white
blood cells</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        allergic reaction
(e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        unusual heartbeat,
sudden unexplained death, heart attack</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        diabetic ketoacidosis
(ketones in the blood and urine) or coma</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        loss of appetite
(anorexia), </span></em><span lang=EN-GB style='color:black'>difficulty in
swallowing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        low sodium level in
the blood</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        suicide attempt and
suicide</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>inability to resist the impulse, drive or temptation to perform an
action that could be harmful to you or others, which may include:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        strong impulse to gamble excessively despite
serious personal or family consequences</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        altered or increased sexual interest and
behaviour of significant concern to you or to others, for example, an increased
sexual drive</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        uncontrollable excessive shopping</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        binge eating (eating large amounts of food in a
short time period) or compulsive eating (eating more food than normal and more
than is needed to satisfy your hunger)</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-        a tendency to wander away</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>Tell your doctor if you experience any of these behaviours; he/she
will discuss ways of managing or reducing the symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        nervousness</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>aggression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        neuroleptic malignant
syndrome ( a syndrome with symptoms such as fever, muscle stiffness, faster
breathing, sweating, reduced consciousness and sudden changes in blood pressure
and heart rate)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        seizure (fits)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>serotonin syndrome (a reaction which may cause feelings of great
happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever,
sweating or rigid muscles)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB>speech disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>heart problems including torsades de pointes,
stopping of the heart, irregularities in heart rhythm that may be due to
abnormal nerve impulses in the heart, abnormal readings during heart
examination (ECG) QT prolongation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        fainting</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>symptoms related to blood clots in the veins
especially in the legs (symptoms include swelling, pain and redness in the
leg), which may travel through blood vessels to the lungs causing chest pain
and difficulty in breathing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        spasm of the muscles
around the voice box</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        accidental inhalation
of food with risk of pneumonia (lung infection)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        inflammation of the
pancreas</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        difficulty swallowing</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        liver failure</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        jaundice (yellowing
of the skin and white part of eyes)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        inflammation of the
liver</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        rash</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><em><span
style='color:black;font-style:normal'>skin </span></em><em><span lang=EN-GB
style='color:black;font-style:normal'>sensitivity to light</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        excessive sweating</span></em></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>serious allergic reactions such as Drug Reaction with Eosinophilia and
Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a
rash on the face and then with an extended rash, high temperature, enlarged
lymph nodes, increased levels of liver enzymes seen in blood tests and an
increase in a type of white blood cell (eosinophilia). </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>muscle weakness, tenderness or pain and
particularly, if at the same time, you feel unwell, have a high temperature or
have dark urine. They may be caused by an abnormal muscle breakdown which can
be life threatening and lead to kidney problems (a condition called
rhabdomyolysis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        difficulty in passing
urine</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        involuntary loss of
urine (incontinence)</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        drug withdrawal
symptoms in new-born infant</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        prolonged and/or
painful erection</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        difficulty
controlling core body temperature or overheating</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        chest pain</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>        swelling of hands,
ankles or feet</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>        </span></em><span
lang=EN-GB style='color:black'>during tests your doctor may find</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        higher amounts alkaline
phosphatase</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>-        fluctuating results during
tests to measure glucose in your blood</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Reporting
of side effects</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or nurse. This includes any possible side effects not listed in this
leaflet. You can also report side effects directly via <span style='background:
silver'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span
style='background:silver'>Appendix V</span></u></a>. By reporting side effects,
you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='text-align:justify'><em><span lang=EN-GB
style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>5.       How to store </span></b></em><b><span
lang=EN-GB style='color:black'>Abilify Maintena</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Keep
this medicine out of the sight and reach of children.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not use this medicine after the expiry date which is stated on the carton and
the pre-filled syringe. The expiry date refers to the last day of that month.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not freeze.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>Keep the pre&#8209;filled syringe in the
outer carton in order to protect from light.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>If the injection is not performed
immediately after reconstitution, the syringe can be kept <em><span
style='font-style:normal'>below 25&nbsp;°C </span></em>for up to 2&nbsp;hours.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>6.       Contents of the pack
and other information</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>What
</span></b></em><b><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>contains</span></em></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        The active substance
is aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Each pre&#8209;filled syringe contains
300&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>After reconstitution each ml of
suspension contains 200&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Each pre&#8209;filled syringe contains
400&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>After reconstitution each ml of
suspension contains 200&nbsp;mg aripiprazole.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        The other ingredients
are</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Powder</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Carmellose sodium, mannitol, sodium
dihydrogen phosphate monohydrate, sodium hydroxide</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><u><span lang=EN-GB
style='color:black;font-style:normal'>Solvent</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Water for injections</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>What
</span></b></em><b><span lang=EN-GB style='color:black'>Abilify Maintena <em><span
style='font-style:normal'>looks like and contents of the pack</span></em></span></b></p>

<p class=MsoNormal><span lang=EN-GB>Abilify Maintena <em><span
style='font-style:normal'>comes in a pre&#8209;filled syringe containing a
white to off-white powder in the front chamber and a clear solvent in the rear
chamber. Your doctor will make it into a suspension that will be given as an
injection.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Single pack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Each
single pack containing one pre&#8209;filled syringe and three hypodermic safety
needles: one 25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge, one 38&nbsp;mm
(1.5&nbsp;inch) 22&nbsp;gauge and one 51&nbsp;mm (2&nbsp;inch) 21&nbsp;gauge.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Multipack</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Bundle
pack of 3 single packs.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Not
all pack sizes may be marketed.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
style='color:black;font-style:normal'>Marketing Authorisation Holder</span></b></em></p>

<p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB>1101 CT, Amsterdam</span></p>

<p class=MsoNormal><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Manufacturer</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>H.
Lundbeck A/S</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Ottiliavej
9, 2500 Valby</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Denmark</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>Elaiapharm</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2881 Route des
Crêtes Z.I Les Bouillides Sophia Antipolis</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>06550 Valbonne</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>France</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>For
any information about this medicine, please contact the local representative of
the Marketing Authorisation Holder:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>België/Belgique/Belgien</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  S.A./N.V.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tél/Tel:&nbsp;+32
  2 535 79 79</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Lietuva</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Export A/S Representative Office</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+359
  2 962 4696</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Luxembourg/Luxemburg</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  S.A.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tél:&nbsp;+32
  2 535 79 79</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:38.1pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:38.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#268;eská republika</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  &#268;eská republika s.r.o.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+420
  225 275 600</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:38.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Magyarország</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Hungaria Kft.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+36
  1 4369980</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:46.1pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:46.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Danmark</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:46.1pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Malta</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Deutschland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma GmbH</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+49
  69 1700860</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Nederland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  B.V.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+31
  20 697 1901</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Eesti</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Norge</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="49%" valign=top style='width:49.64%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Hellas S.A.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&#932;&#951;&#955;:&nbsp;+30
  210 610 5036</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Österreich</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Austria GmbH</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+43
  1 266 91 08</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>España</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceutical S.A.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+34
  93 208 10 20</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Polska</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Poland Sp. z o. o.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel.:&nbsp;+48
  22 626 93 00</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>France</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceutical France SAS</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tél:&nbsp;+33
  (0)1 47 08 00 00</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Portugal</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Portugal Lda</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+351
  21 00 45 900</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
  style='color:black;font-style:normal'>Hrvatska</span></b></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Lundbeck Croatia d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Tel.:&nbsp;+385 1 644 82 63</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><em><b><span lang=EN-GB
  style='color:black;font-style:normal'>România</span></b></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Lundbeck </span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'>Export A/S</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Reprezentanta din </span></em><em><span
  lang=EN-GB style='color:black;font-style:normal'>Romania</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Tel:&nbsp;+40 21319 88 26</span></em></p>
  <p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
  style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Ireland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  (Ireland) Limited</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+353
  1 468 9800</span></em></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Slovenija</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Pharma d.o.o.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel.:&nbsp;+386
  2 229 4500</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Ísland</span></b></em></p>
  <p class=MsoNormal><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Sími: +354 535 7000</span></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Slovenská republika</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Slovensko s.r.o.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+421
  2 5341 42 18</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Italia</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceutical Italy S.r.l</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+39
  02 00 63 27 10</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Suomi/Finland</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lundbeck
  Hellas A.E</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&#932;&#951;&#955;.:&nbsp;+357
  22490305</span></em></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Sverige</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharma Scandinavia AB</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+46
  8 54528660</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Latvija</span></b></em></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>H. Lundbeck
  A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:&nbsp;+45 36301311</span></p>
  </td>
  <td width="50%" colspan=2 valign=top style='width:50.0%;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>United Kingdom</span></b></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Otsuka
  Pharmaceuticals (UK) Ltd.</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Tel:&nbsp;+44
  203 747 5300</span></em></p>
  <p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>
  </td>
 </tr>
 <tr height=0>
  <td width=351 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=351 style='border:none'></td>
  <td width=3 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in <span
style='color:black'>{MM/YYYY}.</span></span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span></em><span lang=EN-GB><a href="http://www.ema.europa.eu/"><u>http://www.ema.europa.eu</u></a><em><span
style='color:black;font-style:normal'>.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<em><span lang=EN-GB style='font-size:11.0pt;color:black;font-style:normal'><br
clear=all style='page-break-before:always'>
</span></em>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>---------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal align=center style='text-align:center'><em><span lang=EN-GB
style='color:black;font-style:normal'>The following information is intended for
healthcare professionals only:</span></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal align=center style='text-align:center'><em><b><span
lang=EN-GB style='color:black;font-style:normal'>INSTRUCTIONS FOR HEALTH CARE
PROFESSIONALS</span></b></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Any
unused medicinal product or waste material should be disposed of in accordance
with local requirements.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 300&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled syringe</span></b></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>Abilify
Maintena 400&nbsp;mg powder and solvent for prolonged-release suspension for
injection in pre&#8209;filled syringe</span></b></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>aripiprazole</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><em><u><span
lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;1: Preparation prior
to reconstitution of the powder</span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Lay
out and confirm that components listed below are provided:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Abilify Maintena
package leaflet and instructions for healthcare professionals.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One Abilify Maintena
pre&#8209;filled syringe.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-        One 25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge hypodermic
safety needle<em><span style='font-style:normal'> with needle protection device.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One 38&nbsp;mm
(1.5&nbsp;inch) 22&nbsp;gauge hypodermic safety needle with needle protection
device.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        One 51&nbsp;mm
(2&nbsp;inch) 21&nbsp;gauge hypodermic safety needle with needle protection
device.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>-        Syringe and needle
instructions.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;2:
Reconstitution of the powder</span></u></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>a)       Push plunger rod slightly
to engage threads. And then, rotate plunger rod until the rod stops rotating to
release diluent. After plunger rod is at complete stop, middle stopper will be
at the indicator line.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt'><em><span style='font-style:normal'><img
border=0 width=624 height=194 src="Abilify%20Maintena_clean_files/image011.png"></span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>b)      Vertically shake the syringe
vigorously for 20&nbsp;seconds until the reconstituted suspension appears
uniform<em><span style='font-style:normal'>. The suspension should be injected
immediately after reconstitution.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt;text-autospace:none'><img border=0 width=624 height=193
src="Abilify%20Maintena_clean_files/image012.png"></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>c)       Visually inspect the
syringe for particulate matter and discoloration prior to administration. The
reconstituted product suspension should appear to be a uniform, homogeneous
suspension that is opaque and milky-white in colour.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>d)      If the injection is not performed
immediately after reconstitution, the syringe can be kept below 25&nbsp;°C for
up to 2&nbsp;hours. Shake the syringe vigorously for at least 20&nbsp;seconds
to re-suspend prior to injection if the syringe has been left for more than
15&nbsp;minutes.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;3:
Injection procedure</span></u></em></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>a)       Twist and pull off Over-cap and
Tip-cap.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;text-autospace:none'><img
border=0 width=624 height=227 src="Abilify%20Maintena_clean_files/image013.png"></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>b)      Select one of the
following hypodermic safety needles depending on the injection site and
patients weight.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=176 valign=top style='width:131.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Body type</span></b></p>
  </td>
  <td width=113 valign=top style='width:84.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Injection site</span></b></p>
  </td>
  <td width=246 valign=top style='width:184.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Needle size</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:131.75pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Non-obese</span></b></p>
  </td>
  <td width=113 valign=top style='width:84.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Deltoid</span></b></p>
  </td>
  <td width=246 valign=top style='width:184.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>25&nbsp;mm (1&nbsp;inch) 23&nbsp;gauge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:131.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=113 valign=top style='width:84.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Gluteal</span></b></p>
  </td>
  <td width=246 valign=top style='width:184.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>38&nbsp;mm (1.5&nbsp;inch) 22&nbsp;gauge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:131.75pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Obese</span></b></p>
  </td>
  <td width=113 valign=top style='width:84.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Deltoid</span></b></p>
  </td>
  <td width=246 valign=top style='width:184.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>38&nbsp;mm (1.5&nbsp;inch)
  22&nbsp;gauge</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:131.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=113 valign=top style='width:84.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Gluteal</span></b></p>
  </td>
  <td width=246 valign=top style='width:184.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>51&nbsp;mm (2&nbsp;inch) 21&nbsp;gauge</span></b></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>c)       While holding the needle
cap, ensure the needle is firmly seated on the safety device with a push. Twist
clockwise until snugly fitted.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;text-autospace:none'><img
border=0 width=624 height=178 src="Abilify%20Maintena_clean_files/image014.png"></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>d)      Then <b>pull </b>needle-cap
straight up.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;text-autospace:none'><img
border=0 width=624 height=165 src="Abilify%20Maintena_clean_files/image015.png"></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>e)       Hold syringe <b>upright and advance
plunger rod slowly to expel the air</b>. If it's not possible to advance
plunger rod to expel the air, check that plunger rod is rotated to a complete
stop. It is not possible to re-suspend after the air in the syringe is
expelled.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt'><em><span style='font-style:normal'><img
border=0 width=624 height=160 src="Abilify%20Maintena_clean_files/image016.png"></span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>f)       Slowly inject into
the gluteal or deltoid muscle. Do not massage the injection site. Care must be
taken to avoid inadvertent injection into the blood vessel. Do not inject into
an area with signs of inflammation, skin damage, lumps and/or bruises. </span></em><span
lang=EN-GB style='color:black'>For deep intramuscular gluteal or deltoid injection
only.</span></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt'><em><span style='font-style:normal'><img
border=0 width=624 height=236 src="Abilify%20Maintena_clean_files/image017.png"></span></em></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB
style='color:black'>Remember to rotate sites of injections between the two
gluteal or deltoid muscles. </span></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB
style='color:black'>If initiating with the two injection start, inject into two
different sites in two different muscles. </span><span lang=EN-GB>DO NOT inject
both injections concomitantly into the same deltoid or gluteal muscle.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:31.5pt'><span lang=EN-GB>For known CYP2D6
poor metabolisers administer in either<s> </s>two separate deltoid muscles or
one deltoid and one gluteal muscle.</span><em><span lang=EN-GB
style='color:black;font-style:normal'> </span></em><span lang=EN-GB>DO NOT
inject into two gluteal muscles.</span></p>

<p class=MsoNormal style='margin-left:31.5pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>Look for signs or symptoms of inadvertent
intravenous administration.</span></em></p>

<p class=MsoNormal style='margin-left:31.5pt'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Step&nbsp;4:
Procedures after injection</span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Engage the needle safety device. Dispose of the needle and
pre&#8209;filled syringe appropriately after injection.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:12.0pt;text-autospace:
none'><img border=0 width=624 height=157
src="Abilify%20Maintena_clean_files/image018.png"></p>

</div>

</body>

</html>
